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Résumé 
La prééclampsie est l’une des causes primaires de mortalité et morbidité 
périnatales, touchant 2-7% des grossesses. Sa prévalence augmente à 10-25% chez 
les femmes hypertendues. Jusqu’à maintenant, aucun traitement, mis à part 
l’accouchement précoce, n’est connu. Néanmoins, plusieurs études 
épidémiologiques suggèrent une diminution de l’incidence de la prééclampsie chez 
les femmes entraînées quoique, ces études sont considérées insuffisantes. Ainsi, le 
but de cette étude est de déterminer si l’entraînement avant et pendant la grossesse 
prévient la maladie dans un modèle animal de prééclampsie superposée à de 
l’hypertension chronique (SPE). 
Nous avons utilisé des souris double transgéniques, surexpirmant la rénine et 
l’angiotensinogène humaines (R+A+), puisqu'elles sont hypertensives à la base, et 
développent plusieurs symptômes de la prééclampsie. Pour l'entraînement, les 
souris ont été mises dans des cages d’exercice 4 semaines avant leur grossesse et y 
sont restées jusqu’au sacrifice.  
L'entraînement physique a prévenu la hausse de pression artérielle en fin de 
gestation présente chez les souris R
+
A
+ sédentaires, possiblement via l’axe de 
l’angiotensine-(1-7). Le rapport entre l’albumine: créatinine a également été réduit 
avec l’entraînement. Les altérations placentaires ont été prévenues chez les souris 
entraînées, améliorant le développement placentaire et fœtal. Ceci était 
accompagné d'une normalisation de sFlt-1 circulant et placentaire. De plus, 
l’augmentation du récepteur à l’angiotensine II de type 1 et la diminution du 
récepteur Mas dans le placenta étaient renversées.  
L’entraînement semble prévenir plusieurs symptômes de la SPE dans un modèle 
animal suggérant qu'il pourrait être d'une grande utilité dans la prévention de la 
maladie chez la femme.   
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Mots-clés : Prééclampsie superposée à de l’hypertension chronique, entraînement 
physique, modèle transgénique, système rénine-angiotensine, placenta.  
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Abstract 
Preeclampsia is among the leading causes of perinatal mortality and morbidity, 
affecting 2-7% of pregnancies. Its incidence increases to 10-25% in already 
hypertensive women. To date, no treatment, aside from delivery, is known.  
Interestingly, several studies have reported that exercise training (ExT) can reduce 
preeclampsia prevalence although the available studies are considered insufficient. 
Therefore, the aim of this study is to determine the impact of ExT when practiced 
before and during gestation on pregnancy outcome in a mouse model of 
preeclampsia superimposed on chronic hypertension (SPE).  
To do so, mice overexpressing both human angiotensinogen and renin (R
+
A
+
) 
were used because they are hypertensive at baseline and they develop many 
hallmark features of SPE. Mice were trained by placing them in a cage with access 
to a running wheel 4 weeks before and during gestation.  
ExT in this study prevented the rise in blood pressure at term observed in the 
sedentary transgenic mothers. This may be realized through an increased activity 
of the angiotensin-(1-7) axis in the aorta. In addition, ExT prevented the increase 
in albumin/creatinine ratio. Moreover, placental alterations were prevented with 
training in transgenic mice, leading to improvements in placental and fetal 
development. Placental mRNA and circulating levels of sFlt-1 were normalized 
with training. Additionally, the increase in angiotensin II type I receptor and the 
decrease in Mas receptor protein were reversed with training.  
ExT appears to prevent many SPE-like features that develop in this animal model 
and may be of use in the prevention of preeclampsia in women.   
 
Keywords: Superimposed preeclampsia on chronic hypertension, exercise 
training, transgenic model, renin-angiotensin system, placenta. 
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Chapter 1 - Introduction 
Preeclampsia (PE) is a pathology that develops during pregnancy. Although the 
disease has been known for centuries, PE remains a disease of theories. Several 
components have been found to be implicated in disease progression, but are not 
seen consistently among all women who develop PE. Importantly, underlying 
medical conditions, like chronic hypertension and diabetes, are known to increase 
a woman’s risk of developing PE. 
 
Although research concerning PE has blossomed in the last 2 decades, treatment 
options are still lacking. The risk of developing this gestational disease will 
continue to rise, given the increase in prevalence of contributing factors (i.e. 
obesity, chronic hypertension and diabetes)[1]. As such, PE prevention appears to 
be the best option for minimizing the prevalence of the disease worldwide.  
 
The purpose of this memoire is thus to investigate the therapeutic effect of 
exercise training in a mouse model of preeclampsia superimposed on chronic 
hypertension (SPE), as well as to investigate potential mechanisms implicated. 
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Chapter 2 - Pregnancy  
2.1 The placenta 
2.1.1 Placentation 
Pregnancy is characterized by the development of a new organ: the placenta. The 
fetal side of the placenta develops from cells originating from the fertilized egg, 
while the maternal side develops from the mother’s uterine tissue. This feto-
maternal organ plays a primordial role throughout pregnancy by providing the 
nutrients and oxygen needed for fetal growth, and eliminating waste products. 
Human pregnancy, much like that of rodents, is characterized by a hemochorial 
placentation, in which the maternal blood comes in direct contact with the fetal 
chorion[2]. 
 
The effectiveness of this placental system is a result of its unique anatomical 
structure. The intricate network of vessels scattered throughout the organ 
effectively perfuses the placenta. In addition, the extensive villous tree structures 
enhance the area available for gas, nutrient and waste exchange for the growing 
fetus. As such, placental vasculogenesis, angiogenesis and pseudovasculogenesis 
are critical processes for a successful pregnancy[3]. It is important to understand 
that the placenta contains both maternal and fetal vessels. On the maternal side, 
remodeling of the vasculature is indispensable to ensure an adequate delivery of 
blood for placental development and fetal growth. The fetus is however 
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responsible for the formation of an intricate vascular tree, which will exponentially 
enhance the surface area available for exchange of substances[4]. 
 
The placental villous tree development begins after implantation[4]. The initial 
step involves the formation of primary villi, which consist of columns of 
cytotrophoblasts, located on the fetal side. These primary villi become secondary 
villi following invasion of the mesenchyme. Once fetal capillaries can be seen 
within the villi structure, they are termed tertiary mesenchymal villi. These three 
steps are repeated throughout pregnancy and contribute to the villous tree 
structure[3]. Some placental villi become anchored to the basement membrane of 
the uterus, while others remain bathed in maternal blood, both of which are 
derived from cytotrophoblasts. Floating villi develop as a result of fusion of 
cytotrophoblasts to form multinucleated syncytiotrophoblasts. Distal 
cytotrophoblasts will attach themselves to the maternal tissue, creating bridges 
between mother and fetus. Additionally, the cytotrophoblast penetrate deeply into 
the uterine and maternal vasculature, via interstitial and endovascular invasion, 
respectively. Endovascular invasion leads to the acquisition of an endothelial 
adhesion molecular phenotype by cytotrophoblasts, a process known as 
pseudovasculogenesis, and the removal of the endothelial and muscular linings of 
uterine arterioles[2, 5]. Endovascular invasion occurs directly via the lumen and 
within the vessel itself, below the endothelium[6]. Vascular remodeling reaches its 
full extent by mid pregnancy, having modified the spiral arteries of the 
  
4 
endometrium and superficial region of the myometrium[6]. The remodeled 
segments are lined exclusively with cytotrophoblasts; endothelial and smooth 
muscle cells are no longer detectable. The disappearance of the muscular tunica 
media converts these normally high resistance vessels into high capacitance (low 
resistance) vessels[7]. Indeed, the diameter of the uterine artery increases two-fold 
by 21 weeks of pregnancy, thereby contributing to an increase in placental 
perfusion and, thus fetal growth[8]. In fact, uterine blood flow increases 20-fold 
during pregnancy as a result of this remodeling[9]. These vessels also become 
unresponsive to vasoactive substances as they lack an endothelium, thereby 
maintaining an adequate and consistent blood flow to the growing fetus.   
2.1.2 Role of oxygen tension  
The first trimester is of critical importance for the success of a pregnancy. During 
this period, changes in oxygen tension modulate cytotrophoblastic proliferation 
and differentiation[10, 11]. Blood flow to the placenta is initially minimal, creating 
a relatively hypoxic environment. Indeed, oxygen tension is suspected to be 
around 20 and 40 mmHg at 8-10 weeks in the intervillous space of the 
endometrium and decidua, respectively, in comparison to 60 and 45 mmHg, 
respectively, when evaluated at 12-13 weeks, after trophoblastic invasion has 
begun[12]. Very little endovascular invasion takes place at low oxygen tensions, 
further contributing to low placental perfusion. This stage of pregnancy is thus 
characterized by a rapid placental growth and contributes to the future growth and 
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development of the fetus by ensuring the placenta’s ability to promote gas, nutrient 
and waste exchange.  
Under low oxygen tension, cytotrophoblasts are highly proliferative[10]. Indeed, 
in vitro studies have demonstrated that cyclin B, a protein required for entering the 
mitosis phase of the cell cycle, is significantly increased under low oxygen tension 
(oxygen partial pressure (pO2) of 2%), compared to standard conditions (pO2 of 
20%)[10]. Additionally, this group also observed a decrease in p21
WF1/CIP1
, a 
protein involved in cell cycle arrest under hypoxic conditions, demonstrating a 
reduction in mitotic inhibition thereby favouring proliferation. This reduction in 
p21 is likely mediated in part by the transforming growth factor (TGF) 3, in 
line with the premise that TGF inhibits trophoblastic invasion[13]. This highly 
proliferative state is accompanied by a concomitant decrease in the cell’s ability to 
differentiate, as demonstrated by specific antigen expression, such as a reduction 
in 1 integrin required for invasiveness[10]. As proliferation continues to take 
place, peripheral cytotrophoblasts gain access to maternal arterial blood, rich in 
oxygen.  Cytotrophoblastic cells go from being proliferative to invasive around 
week 10[10, 14, 15].This change in oxygen tension consequently causes a decrease 
in the cells’ ability to proliferate[5]. Instead, the endovascular cytotrophoblasts 
begin to differentiate and acquire an endothelial-like expression pattern of cell 
adhesion molecules, which enhances their motility and invasiveness[5]. Indeed, in 
vitro studies have demonstrated that an increase in oxygen modifies V integrin 
family members expression spatially, notably increasing 11 and 33 integrins 
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which are specific to endothelial cells, and decreasing 64 and 63 integrins, 
which are characteristic of epithelial cells[5, 16].  Invasive trophoblasts also have a 
reduced E-cadherin (epithelial cadherin) and increased VE-cadherin (endothelial 
cadherin) expression, providing further evidence that cytotrophoblasts undergo 
differentiation by mimicking endothelial cell antigen expression[5]. Relatively 
high oxygen tension thus promotes differentiation of cytotrophoblasts and 
endovascular invasion, and may explain why invasion of the arterial rather than 
the venous side of the uterine circulation is favoured.  
 
Oxygen tension is known to modulate hypoxia-inducible factor-1 expression 
(HIF-1[17]. Under hypoxic conditions, much like during early pregnancy, HIF-
1 levels are increased, as is TGF-3[14]. HIF-1 stimulates the expression of the 
vascular endothelial growth factor (VEGF), a potent mediator of angiogenesis and 
vasodilation. This family of angiogenic factors, along with angiopoietins, are 
critical for pregnancy. The VEGF family is involved in endothelial cell 
proliferation, angiogenesis, vascular permeability and inflammation while 
angiopoietins are involved in endothelial survival, capillary sprouting and vascular 
stabilization[18, 19]. Angiogenesis and vasculogenesis dominate during the first 
trimester of pregnancy, when HIF-1 is elevated. By 10 weeks of pregnancy, the 
expression of HIF-1and TGF- are diminished, which is in line with the 
increase in oxygen tension that occurs following trophoblastic invasion[14]. 
Subsequently, a decrease in VEGF occurs as pregnancy progresses[20]. 
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Importantly, modulation in VEGF levels has been postulated to also contribute to 
trophoblastic invasiveness since VEGF and VEGFR mRNA expression are 
decreased in biopsies of preeclamptic placentas[21].  
2.2 Cardiovascular and hemodynamic adaptations 
Pregnancy is a physiological process that necessitates cardiovascular and 
hemodynamic adaptations to ensure the survival of both mother and fetus. The 
systemic renin-angiotensin system (RAS) is a key player in many of these changes 
as it is critical for arterial pressure (AP) control as well as fluid and salt 
homeostasis in the non-pregnant state (see Figure 1 for detailed depiction of the 
RAS). Normal pregnancy is characterized by an increase in the circulating levels 
of prorenin, renin and angiotensinogen[22]. Via this cascade, circulating levels of 
angiotensin II (AngII) are increased, although this is coupled with a diminished 
endothelial sensitivity to AngII[23]. AngII is the dominant physiologically active 
compound produced by the RAS and has several downstream effects, mediated by 
the AngII type 1 receptor (AT1R). Notably, AngII stimulates vasoconstriction, and 
the release of aldosterone and antidiuretic hormone (ADH). The increase in 
circulating levels of aldosterone and ADH (also known as arginine vasopressin 
(AVP)) during pregnancy contributes to the enhanced renal sodium and water 
reabsorption, respectively, observed in this condition. Although the systemic RAS 
plays a pivotal role, the implication of the local RASs cannot be ignored. Their 
roles have become more apparent as a result of their investigation during diseased-
states. For instance, in patients with cerebral aneurysms, hypertension and renal 
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disease present with inappropriate activation of the RAS thereby contributing to 
the disease development[24, 25]. Moreover, a functional uteroplacental RAS also 
exists as all of its components are expressed at the level of the uterus, and the 
placental and fetal membranes[26]. The fetal RAS is hypothesized to be implicated 
in fetoplacental blood flow regulation, while that on the maternal side is thought to 
be involved in the vascular remodelling required for normal pregnancy[22]. 
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Figure 1: The RAS and the effects of the different components via their 
respective receptors 
Thin arrows describe the conversion reactions that make up the RAS pathway. 
Thick arrows demonstrate the receptor(s) by which these RAS peptides mediate 
their effects. ACE, angiotensin-converting enzyme; ADH, antidiuretic hormone; 
AMPA, Aminopeptidase A; AT1R, angiotensin II type 1 receptor; ICAM-1, 
intercellular adhesion molecule-1; IL-6; interleukin-6; IRAP, insulin regulated 
aminopeptidase; MasR, angiotensin-(1-7) Mas oncogene receptor; MCP-1, 
monocyte chemoattractant protein-1; NEP, neutral endopeptidase; NF-, nuclear 
factor kappa activated by B cells; PAI-1, plasminogen activator inhibitor-1; (P)RR, 
Angiotensinogen 
Angiotensin I 
Angiotensin II 
Angiotensin IV 
Angiotensin-(1-9) 
Angiotensin-(1-7) 
Renin 
Apoptosis 
Fibrosis 
Hypertrophy 
Enhanced contractility 
(P)RR 
Vasodilation; antihypertrophic, 
antifibrotic & antithrombotic effects 
IRAP – Angiotensin IV reecptor 
Vasodilation; antiproliferation; antihypertrophic, 
antifibrotic & antithrombotic effects 
AT2R 
Vasoconstriction; sFlt-1, ADH & aldosterone secretion; 
proliferation; hypertrophy; Fibrosis; oxidative stress 
AT1R 
Vasodilation; 
Induces NF-,  
MCP-1, Il-6, TNF,  
ICAM-1, PAI-1 
MasR 
AMPM 
AMPA 
ACE 
ACE2 
NEP 
Tonin, 
Cathepsin G 
Angiotensin III 
ACE2 
ACE, NEP 
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pro-renin receptor; TNF, tumor necrosis factor . 
 
The pregnancy-induced volume expansion is characterized by a 45-55% increase 
in extracellular volume, including a 20-30% elevation in plasma volume[27]. An 
adequate increase in plasma volume will help maintain an adequate blood flow, 
and thus nutrient and oxygen delivery, to the growing fetus. Moreover, the 
increase in circulating blood volume gives rise to a proportionate increase in stroke 
volume (SV) and thus cardiac output (CO), which will be maintained throughout 
pregnancy[28]. As a result of the pregnancy-induced hypervolemia, heart rate 
(HR) also increases to maintain organ perfusion[29]. Paradoxically, AP does not 
increase during normal pregnancy. In fact, AP decreases during the first and 
second trimester[30]. During the third trimester, AP rises, returning to pre-
pregnancy baseline values, and in some cases somewhat higher, by the end of 
pregnancy[31].  
 
The vasodilatory state of pregnancy is primarily mediated by a pregnancy-induced 
reduced response to vasoconstrictors, notably AngII, vasopressin and 
norepinephrine, by smooth muscle cells and the endothelium[22, 32, 33]. This 
pressor response is not mediated by changes in receptor affinity or receptor 
number, but rather results from an increased activity and expression of 
angiotensin-converting enzyme 2 (ACE2) during pregnancy[34, 35]. Enhanced 
ACE2 expression was observed in the kidney, the placenta and to a lesser extent, 
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the uterus[34, 36]. ACE2, a homologue of the angiotensin-converting enzyme 
(ACE), converts AngII into the vasodilatory angiotensin-(1-7) (Ang-(1-7)) (see 
Figure 2)[37, 38]. Indeed, plasma Ang-(1-7) is increased during pregnancy in 
women[39]. Additionally, animal studies have demonstrated enhanced Ang-(1-7) 
expression in the uteroplacental unit and kidneys[34, 40]. Further supporting the 
role of ACE2 on blood pressure control are studies demonstrating a reduction in 
ACE2 expression in several hypertensive animal models[41, 42]. Furthermore, 
Gurley et al have observed an increase in baseline blood pressure in certain 
genetic strains of ACE2-deficient mice[43]. Degradation of AngII and production 
of Ang-(1-7) by ACE2 therefore counterbalances the AngII mediated vasopressor 
effect. Ang-(1-7) mediates its effects by binding to the Ang-(1-7) Mas oncogene 
receptor (MasR). MasR is a G-protein coupled receptors that ultimately leads to 
the nitric oxide (NO) production by endothelial nitric oxide synthase (eNOS) and 
prostaglandin production[44]. MasR may also be implicated in the pregnancy-
induced pressor response as Yamaleyeva and colleagues have noted an increase in 
MasR mRNA expression in the utero-placental unit of an animal model during 
early gestation[45]. 
Another important component that contributes to reducing the vasoconstrictive 
tone of pregnancy involves the generation of vasodilatory mediators like NO. NO 
is a biologically active signalling molecule that binds soluble guanylate cyclase in 
smooth muscle cells, and in doing so, produces cGMP (cyclic guanosine 
monophosphate). cGMP activates protein kinase G which ultimately causes 
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smooth muscle relaxation. NO is generated by NO synthase (NOS) from L-
arginine, O2 and NADPH. There exists three subtypes of this enzyme: endothelial, 
inducible and neuronal NOS (eNOS, iNOS and nNOS, respectively)[46]. 
Inhibition of NOS prevents the pregnancy-induced pressure drop in rats, 
implicating this system in AP control[47]. Several possible mechanisms exist for 
eNOS activation during pregnancy. Enhanced flow-induced shear stress resulting 
from pregnancy-induced hypervolemia contributes to NO production[48]. As 
previously mentioned, the binding of Ang-(1-7) to MasR leads to eNOS activation 
and NO production, through the activation of Akt-dependent pathways[44]. In 
vitro studies have demonstrated the induction of NO production by estrogen 
through the effects of eNOS[1, 49]. Elevated estrogen levels throughout pregnancy 
contribute to the observed vasodilatory state and maintained endothelial function. 
Abnormal estrogen levels during pregnancy may be involved in gestational 
pathologies; similarly to the increased cardiovascular risk observed in post-
menopausal women[50-52].  
Systemic and renal NO production are enhanced during pregnancy, which 
accounts for the increase in renal blood flow (RBF) and glomerular filtration rate 
(GFR), along with a decrease in total peripheral resistance (TPR)[23, 28, 53].  
Another possible mediator involved in the vasopressor response of pregnancy 
includes the insulin-regulated aminopeptidase (IRAP), also known as the AngIV 
receptor. It is expressed by several tissues, notably the placenta and the heart. In 
the circulation, this enzyme not only degrades oxytocin (OT), but also 
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vasoconstrictors such as angiotensin III (AngIII), and promoters of cardiac 
hypertrophy, such as AVP[54, 55]. Circulating levels and activity of IRAP have 
been reported to be increased during pregnancy[56] and as such, may play a role in 
maintaining homeostasis during pregnancy[57]. See figure 2 for a summary of the 
mediators implicated in AP control during pregnancy.  
The homeostatic adaptations during pregnancy promote the development of a 
physiological cardiac hypertrophy primarily due to an increase in left ventricular 
(LV) thickness[23]. LV function is also improved because of a higher preload, a 
lower afterload and improved intrinsic contractile properties of the 
myocardium[23]. Pregnancy, although physiological, is temporary, and as a result, 
cardiac properties and function return to pre-pregnancy values following delivery, 
as does AP, SV and HR.  
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Figure 2 : Regulators of gestational blood pressure control 
White boxes depict the mechanisms implicated in blood pressure control during 
pregnancy. Ang-(1-7) angiotensin-(1-7); AngII, angiotensin II; AngIII, angiotensin 
III; AVP, arginine vasopressin; ET-1, endothelin-1; IRAP, insulin-regulated 
aminopeptidase; NE, Norepinephrine; NO, nitric oxide; NOS, nitric oxide 
synthase; PGI2, prostacyclin; TxA2, thromboxane A2. 
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Chapter 3 - Preeclampsia 
3.1 Symptoms 
 Mild preeclampsia (PE) is diagnosed by an increase in AP above 140/90 mmHg 
and de novo proteinuria above 300mg/24h after 20 weeks of gestation[58] while 
severe PE is defined by a diastolic and systolic pressure above 110 and 160mmHg, 
respectively with the new appearance of proteinuria[59].. As one would expect, the 
risk of perinatal mortality and morbidity is heightened in cases of severe PE [60].  
SPE is characterized by a significant increase in AP (above their already 
hypertensive values) and de novo proteinuria after 20 weeks of pregnancy[61]. 
SPE is difficult to diagnose in patients with undiagnosed pre-pregnancy 
hypertension because, these women can present with normal AP during their first 
and second trimester as a result of the pregnancy-induced AP decrease. The 
diagnosis is often made several months after delivery, when AP has still not 
returned to its normal range.  
It is important to understand that PE is a systemic disease that affects virtually 
every organ, either overtly or subclinically, depending on the cause and severity of 
the disease. As such, the clinical spectrum of PE varies enormously. This 
heterogeneity is likely a result of the existence of multiple etiologies[62]. 
Consequently, several treatment options will likely have to be identified/developed 
according to these respective subtypes.  
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PE is normally associated with reversible renal and cardiovascular anatomical and 
pathophysiological adaptations. The cardiovascular adaptations normally ensue as 
a result of the increase in afterload[63]. Indeed, high AP is known to cause 
concentric cardiac hypertrophy in men and non-pregnant women[64]. Similar 
cardiac findings are observed among preeclamptic patients[65]. Paradoxically, PE 
is normally associated with a hypovolemic state. Interestingly, preeclamptic 
women are more susceptible to cardiovascular diseases (CVD) later in life[66, 67]. 
This may be a result of the development of a pathological cardiac hypertrophy or 
may be a manifestation of a pre-existing medical condition, which merely 
progresses with time to CVD, irrespective of whether the patient developed PE, 
rather than the actual cause of CVD post-PE.  
GFR and RBF are normally increased in normal pregnancy as a result of the 
greater blood volume[28, 30]. However, in PE, both of these components are 
diminished compared to normal pregnancy[68], resulting in hyperuricemia[69]. 
Hyperuricemia, if severe, can cause renal failure[70], thereby creating a vicious 
circle, in addition to being a risk factor for hypertension and CVD[71]. Systemic 
endothelial dysfunction, commonly observed during PE, can also cause a reduction 
in both GFR and RBF[72]. Worsening proteinuria or sudden oliguria are signs of 
severe PE. In very severe cases, kidney failure can arise, necessitating dialysis for 
the remainder of a woman’s life. 
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Overt hepatic damage is also usually indicative of severe PE. Generally, 10-15% 
of PE patients develop HELLP syndrome, which is characterized by hemolysis, 
elevated liver enzymes and low platelet count[73], and normally requires induction 
of fetal delivery. A correlation has been reported between low platelet count and 
perinatal mortality and morbidity[74], as well as between high serum hepatic 
transaminases levels, a marker of liver damage, and PE severity[75]. HELLP 
syndrome normally develops in response to over-activation of the coagulation 
cascade as is observed during PE; thereby promoting the development of 
microthrombi and giving rise to ischemia and necrosis[35].  
 
Less than 1% of PE cases progress to eclampsia, a disease characterized by 
convulsions[76]. Those PE patients that do however develop eclampsia will 
sometimes present with neurological impairment, including headaches, visual 
symptoms, changes in mental status and lethargy, as a result of cerebral 
hyperperfusion-induced edema[77]. These patients require close monitoring as an 
increase in cerebral AP may lead to stroke. Although severe, the prevalence of 
eclampsia has decreased significantly in the last 20 years because of the use of 
magnesium sulfate to prevent the progression of PE to eclampsia[78]. 
 
Fetal prematurity, resulting from the necessity to induce premature delivery to 
protect the mother from PE-induced maternal complications is responsible for 
elevated rates of fetal mortality and morbidity[34]. Fetal symptoms will thus vary 
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depending on the severity of PE. Since no other treatment exists aside from 
inducing fetal delivery, fetal consequences are common. These premature neonates 
may suffer from intra-uterine growth restriction (IUGR). Suboptimal perfusion 
resulting from PE-induced placental alterations is likely responsible for IUGR 
[79]. Prematurity and IUGR may have developmental repercussions later in 
life[34].  
Although PE symptoms generally disappear following delivery, these women 
remain at risk of CVD as previously mentioned earlier in the text. Indeed, several 
studies have observed an increased risk of CVD in women previously diagnosed 
with PE[66, 67] and research is now focusing on this issue to better protect these 
women from prospective diseases. PE will have long-term implications on 
women’s health and their diagnosis should be used as a marker for underlying 
diseased state. Similarly, although the apparent fetal consequences of PE are those 
associated with preterm delivery and IUGR, fetal programming is likely intricately 
implicated[80-82]. Alterations in placental development, fetal substrate 
availability and, of importance, the hormonal environment will arise as a result of 
PE-associated placental hypoxia and oxidative stress. Exposure to high levels of 
glucocorticoids and nutrient deprivation will alter the expression of transcription 
factors, receptors, and cell mediators, and in doing so, will increase the fetus’ risk 
of disorders of adulthood, like CVD, neuroendocrine disorders and psychiatric 
disorders, among others[83].  
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3.2 Risk factors of PE 
3.2.1 Epidemiology 
PE is observed in about 2-7% of healthy nulliparous pregnancies[59, 84]. 
MacGillivray noted in a well characterized Scottish population that 5.6% of 
women who experienced a preeclamptic birth were primiparous, while 0.3% of 
cases occurred during a second pregnancy[85]. It is commonly found in women of 
a young age, during their first pregnancy[62]. Although an association appears to 
exist between young age and PE, nulliparity may be the source for this apparent 
link. It is hypothesized that desensitization or tolerance to paternal antigens is 
responsible for protecting the mother during future pregnancies with the same 
mate[86]. Therefore, all factors that modify maternal recognition of paternal 
antigens tend to have an effect. Indeed, women who have had an abortion[87-89] 
have a reduced risk of PE while the frequency of PE is superior in women using 
donor sperm insemination[90] and among those using barrier method 
contraceptives[91]. Importantly, a pregnancy with a new mate eliminates the 
protection that was once conferred, lending support to the implication of an 
immunogenic response as a possible mechanism for PE development[92]. Further 
supporting this hypothesis is the observation that pregnant women are more likely 
to develop PE if their partner has previously given rise to a preeclamptic 
pregnancy[93, 94]. The so-called “dangerous father” therefore demonstrates the 
existence of paternal factors that contribute to PE risk.  
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PE prevalence is heightened in women with CVD, including chronic hypertension, 
metabolic syndrome, obesity, pre-gestational diabetes mellitus, dyslipidemia, and 
pre-existing thrombophilias[62]. Many of these diseases share common 
characteristics, like systemic inflammation and endothelial dysfunction. 
Unfortunately, the rising incidence of CVD will contribute to a further increase in 
PE prevalence. There is a higher occurrence of PE among women of African 
descent, which may be due to the higher incidence of hypertension among this 
group of women[95].  
 
It is estimated that 10-20% of women of childbearing age suffer from hypertension 
worldwide[83]. This CVD is characterized by an increase in AP, above 
140/90mmHg[96]. If left uncontrolled, high AP can lead to stroke and heart attack, 
among other CVD[97]. Studies have shown a direct link between lowering AP and 
a decreased risk of CVD and death[98]. Underlying hypertension is an important 
risk factor for PE, as the prevalence of SPE increases to 10-25% in previously 
hypertensive women[99, 100]. During pregnancy however, these women also 
experience a physiological decrease in AP as great as 15-20 mmHg, rendering it 
difficult to diagnose SPE in previously undiagnosed hypertensive mothers[101]. 
An increase in AP alone poses a significant risk on fetal outcome[99]. Indeed, 
perinatal mortality is higher among pregnancies associated with hypertension, with 
a relative risk of 2.3 compared to normotensive, uncomplicated pregnancies[99]. 
In an attempt to control AP during pregnancy, care must be taken when choosing a 
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treatment option, as exposure to anti-hypertensive medications can pose major 
risks to the fetus. Methyldopa is presently the preferred drug prescribed to 
hypertensive women during pregnancy, as many others are contraindicated[95, 
102].  Inhibitors of the RAS, like AT1 receptor blockers (ARB) or angiotensin-
converting enzyme inhibitors (ACEI), have been linked with fetal abnormalities 
and neonatal death[35]. Interestingly, a recent study by Diav-Citrin et al. fails to 
observe ARB- and ACEI-mediated teratogenic effects when used during the first 
trimester[103]. The use of diuretics is also discouraged because of its effect on 
plasma volume, particularly as PE is associated with a hypovolemic state. 
Importantly, controlling AP by antihypertensive medication does not treat the 
disease; it minimizes the risk of developing severe PE. When antihypertensive 
therapies are not effective at controlling AP, fetal delivery is required, in an 
attempt to limit negative pregnancy outcomes.  
 
For a more complete list of known PE risk factors, see table 1 below.  
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Table 1: PE risk factors 
Young age (less than 20 years) 
Old age  (above 45 years)                                                   
Primiparity                                                      
New Paternity                                                                       
Prolonged interval between 
pregnancies                                                            
Excessive placental size                                                             
Hydrops fetalis*                                                                      
Multifetal pregnancies 
Lack of previous abortion 
Barrier contraception 
Donor oocyte or insemination 
Intracytoplasmic sperm injection  
Polycystic ovarian syndrome  
Low calcium intake     
Short-term oral or semen exposure 
(shorter cohabitation period)                                                           
Family history (CVD) 
Adiposity
Prepregnancy obesity 
Prepregnancy diabetes mellitus 
Prepregnancy hypertension (chronic 
hypertension 
Weight gain during pregnancy 
Thrombophilia
Sedentary lifestyle 
Lack of smoking 
Dietary factors  
Hyperglycemia 
Insulin resistance 
African American ethnicity 
Triploidy   
Hydatiform mole** 
* Hydrops fetalis: Fetal disorder characterized by an abnormal accumulation of 
fluide in a minimum of two (2) fetal compartments[104].  
* Hyaditiform mole: Abnormal pregnancy in which the embryo, amniotic 
membrane and cord are lacking[105]. 
3.2.2 Genetic factors   
PE is commonly found within members of a same family, providing evidence for 
the existence of genetics risk factors. For example, a woman born from a 
preeclamptic birth runs a greater risk (20-40%) of developing PE [106, 107]. 
Among sisters, the risk can climb to 11-37%[108]. The daughter of a man who 
was born from a preeclamptic birth is also at a greater risk of suffering from 
PE[109]. Paternal genes may play a different kind of role in disease development, 
as depicted by the “dangerous father”, triggering an abnormal immune response 
against seminal antigens[92, 110]. The link between genetics and PE is far from 
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simple however. There are various genetic components in play, in addition to their 
interaction with the environment, which can predispose an individual to this 
gestational disease[34]. Alone, genetics are unlikely to be responsible for inducing 
the disease, but they are likely to be implicated in altering an individual’s 
susceptibility[111].  
Association studies have helped elucidate common alleles that are found in women 
who develop PE. Those extensively studied include methylenetetrahydrofolate 
reductase (MTHFR), factor V Leiden, prothrombin (factor II), angiotensinogen 
(AGT), ACE, endothelial NOS (also referred to as NOS3) and human leukocyte 
antigen (HLA)[112]. MTHFR, factor II and V are involved in inherited 
thrombophilias, which is a known risk factor for PE. AGT and ACE are critical 
players in the classical RAS, which has been postulated to be implicated in PE 
because circulating levels of several RAS components are abnormal in this 
condition, as mentioned previously. For instance, the AGT T235 polymorphism 
predisposes women to essential hypertension and, thus, PE, by enhancing plasma 
and tissue AGT expression, ultimately leading to an increased production of 
AngII[113, 114]. As previously mentioned, PE is characterized by systemic 
endothelial dysfunction, rendering the endothelium more responsive to 
vasoconstrictors and less so to vasodilators.  As such, NOS3 is involved in the 
maintenance of endothelial function. The NOS3 variant Glu298Asp, linked with 
PE minimize the availability of NO, thereby reducing the potential extent of 
vasodilation and steering it more towards a vasoconstrictive state[115, 116]. 
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Lastly, HLAs are involved in maternal immune response during pregnancy. The 
human leukocyte type 2 DR antigens (HLA-DR) are responsible for paternally-
derived fetal antigen recognition by the mother. An increase in HLA-DR 
homozygosity in both parents is associated with the generation of a preeclamptic 
birth, suggesting that the absence of genetic compatibility between mother and 
father may play a role in PE initiation[117]. Polymorphisms in other candidate 
genes have also been identified, including glutathione S-transferase[118]. 
 
It is important to understand that maternal and fetal genotypes are not identical. 
Additionally, the placenta and fetus originate from maternal and paternal genes 
and thus represents an allograph. An abnormal immune response by the mother 
could be at the heart of the disease. Interestingly, diseases related to T-cell 
immunodeficiency, like HIV, have a lower risk of developing PE[119, 120].  
 
3.2.3 Dietary supplementation, stress, smoking and exercise training 
To date, the only cure for PE is delivery of the fetus. There are however 
consequences to this option, as fetal growth and development may be jeopardized 
in the process if early delivery is chosen. As a result, research has focused on 
identifying possible pharmaceutical therapies and lifestyle modifications to 
prevent and control progression of the disease. 
Unfortunately, most of the studies investigating the role of dietary supplements in 
PE have shown no beneficial role. Although oxidative stress has been implicated 
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in PE development, antioxidant supplementation has been investigated without 
much success[121]. Interestingly, many of the studies investigating the effects of 
antioxidants on PE prevention begin supplementation after 14-16 weeks of 
gestation. At this stage of pregnancy, the processes involved in PE development 
have already been initiated. Antioxidant supplementation may not be sufficient at 
this stage to counter the systemic oxidative stress and its damages. Calcium 
supplementation was shown to be effective only among women with a reduced 
calcium intake[122]. There is recent evidence indicating that vitamin D 
supplementation prior to and/or during pregnancy can prevent PE in women[123], 
although further investigation is required as the exact mechanisms by which 
vitamin D positively impacts pregnancy remain unclear.  
Chronic stress is an environmental factor that can negatively affect CVD, certain 
cancers, respiratory diseases, etc[124]. Mothers living or working in a stress-
ridden environment during pregnancy have been shown to be at a greater risk of 
delivering prematurely[125]. Additionally, stress at work has been associated with 
an increased risk of PE[126]. For instance, female resident physicians were more 
likely to become preeclamptic compared to the wives of their male 
classmates[127].  
Also, although there are many adverse effects of smoking during pregnancy, 
including fetal growth restriction and placental abruption, it is interesting to note 
that smokers have a reduced risk of developing PE[128]. The protective effect of 
smoking is thought to be mediated by carbon monoxide in the placenta[129]. It is 
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reported that carbon monoxide reduces the production of anti-angiogenic 
mediators which can cause endothelial dysfunction and thus lead to hypertension 
and proteinuria[130].  
 
The role of exercise training in modulating PE risk will be discussed in detail in 
chapter 3. 
 
3.3 Etiologies of PE 
PE is a disease of theories; however our understanding of the possible etiologies 
has increased drastically in the last two decades. There are several mechanisms 
that have been implicated in the development of PE including abnormal 
placentation, endothelial dysfunction, oxidative stress, inflammation, immunity 
and the RAS[62]. 
 
3.3.1 Abnormal placentation 
The role of the placenta has long been suspected, particularly given that the only 
treatment for PE is induction of fetal delivery and as such, removal of the placenta. 
Moreover, the disease may occur during molar and is more frequent during 
multiple pregnancies, further lending support to a placental role[131, 132]. 
Placental abnormalities is among the most supported hypotheses for PE 
development. Indeed, preeclamptic placentas are characterized by the presence of 
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sclerotic villi, a loss of intermediate villi, a growth in intervillous space and an 
abundance of syncytial knots[133]. The vasculature is characterized by the 
presence of foam cells, fibrinoid necrosis and perivascular lymphocyte infiltration, 
possibly a result of an immunological response[134]. Vascular and thrombotic 
lesions are detected in vessels on both the fetal and maternal side of the 
uteroplacental unit and may contribute to the diminished placental perfusion[135] 
and tissue hypoxia. It is estimated that this reduction in placental blood flow is of 
the order of 50-70%[136]. Importantly, reduced uterine perfusion pressure has 
been identified as an animal model of PE[137, 138]. Further aggravating this 
situation is the abundance of vasoconstrictors, like thromboxane A2 and 
endothelin-1, in addition to an increased sensitivity to AngII without any changes 
in that of vasodilators, like prostacyclin (PGI2), NO and Ang-(1-7)[139-141]. The 
overpowering vasoconstrictive effect, which diminishes placental perfusion, 
results from a superficial invasion of the spiral arteries by cytotrophoblasts and 
defective pseudovasculogenesis. Furthermore, the failure of trophoblasts to acquire 
an endothelial-like adhesion molecule phenotype ensures that the vessels retain 
their elastic and smooth muscle-like properties, and continue responding to 
circulating vasoconstrictive substances, further decreasing placental perfusion[135, 
142]. Together, adequate placental blood flow is jeopardized, as is fetal growth 
and development.  
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The soluble Fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) are 
anti-angiogenic mediators that have been found to be elevated during PE[143, 
144]. Hypoxia causes the placenta to synthesize and release these mediators into 
the circulation, which is thought to further impact placental development and 
aggravate hypoxia. Placental sFlt-1 production is also induced by pro-
inflammatory cytokines, like TNF-, and its secretion is stimulated by AT1R[145, 
146]. In addition to their local effects in the placenta, these mediators enter the 
circulation and promote systemic endothelial dysfunction, inflammatory responses 
and oxidative stress. 
sFlt1 is a splice variant of the vascular endothelial growth factor receptor (VEGFR 
or Flt-1), which lacks the transmembrane domain. It therefore circulates in the 
blood and binds circulating VEGF and placental growth factor (PlGF) which 
reduces their capacity to attach to their membrane receptors, VEGFR1 (also named 
Flt-1). As such, the effects on angiogenesis and vascular permeability are 
blunted[147]. Decreased VEGF availability may also prevent 
pseudovasculogenesis, since conversion of hematopoietic stem cells into 
endothelial cells is induced  by VEGF[148]. In addition, under hypoxic conditions, 
a decrease in PlGF gene expression along with an increase in VEGF gene 
expression in cytotrophoblasts and syncytiotrophoblasts is observed in vitro[149, 
150]. Although counterintuitive, the increase in VEGF expression may merely be a 
compensatory mechanism to counteract the increase in circulating sFlt-1. Finally, 
in vitro studies have demonstrated that sFlt-1 inhibits cytotrophoblastic invasion 
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and differentiation[151] by blocking ligand binding. Indeed, the expression of 
integrin 1, which is normally expressed by endovascular cytotrophoblasts, was 
significantly reduced in the presence of sFlt-1[151]. Moreover, Zhou et al. also 
observed an increase in TUNEL staining, thereby demonstrating higher levels of 
apoptosis[151]. Interestingly however, Flt-1 deletion in an animal model does not 
affect placentation, suggesting that sFlt-1 during PE may not be implicated in 
placental alterations. This however cannot be concluded with certainty since sFlt-1 
modulates Flt-1, Flk-1 and neuropilin signalling[48, 152]. Moreover, 
administration of sFlt-1 to pregnant and non-pregnant rats causes hypertension and 
proteinuria, similarly to the symptoms observed during PE[153]. Similarly, 
overexpressing sFlt-1 in mice led to the development of PE-like manifestations in 
pregnant mice, however Lu et al did not observe similar symptoms when 
transfecting non-pregnant mice[154]. Thus far, sFlt-1 overexpression has been 
depicted as a deleterious anti-angiogenic state, however lower levels of sFlt-1 
during the first trimester have been observed in women who go on to miscarry 
compared to women who deliver healthy babies[39]. It is important to note that 
some women with elevated sFlt1 levels do not develop PE, and vice versa, 
supporting the existence of various etiologies for this disease[143, 155].  Elevated 
plasma sFlt-1 levels are therefore not specific to preeclampsia. 
Endoglin, a coreceptor for TGF 1 and 3, is released by the placenta into the 
maternal circulation in cases of PE[144]. Antagonization of TGF1 and TGF3 by 
sEng inhibits TGF signalling pathways, which include eNOS phosphorylation 
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thereby hindering systemic endothelial function[156-158]. Animal models have 
shown that sEng alone cannot give rise to all PE features, but does cause an 
increase in mean arterial pressure (MAP) in pregnant rats[144]. The effects of 
sEng adrenoviral expression in non-pregnant mice was not however investigated in 
this study. Animal models in which both sFlt1 and sEng were overexpressed 
caused severe PE-like features, including a more important increase in MAP 
compared to sEng alone, proteinuria, HELLP syndrome and fetal growth 
restriction in pregnant rats and severe vascular injury among their non-pregnant 
counterparts[144]. These antiangiogenic components thus seem to work together 
to mediate systemic endothelial dysfunction, inflammation and oxidative 
stress[159].   
Abnormal placentation will negatively impact fetal growth and development, 
possibly resulting in fetal growth restriction. Fetal growth restriction does not 
however occur in all women affected by PE, suggesting that the extent of 
trophoblastic invasion relates to disease severity and that compensatory 
mechanisms may arise to minimize the effects on the fetus.   
 
3.3.2 Endothelial dysfunction 
The endothelium consists of a layer of cells separating vascular smooth muscle 
cells from circulating blood components. It is responsible for modulating vascular 
tone and permeability, and plays a critical role in targeting immune cells to the site 
of injury and controlling the coagulation cascade[160]. Systemic endothelial cell 
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injury, as is the case in PE, will consequently affect the endothelium’s ability to 
adequately respond to vasoactive substances, to control vascular permeability and 
to maintain hemostasis[161]. Systemic endothelial dysfunction is observed 
biochemically by the synthesis and secretion of markers of endothelial cell injury, 
like endothelin-1, fibronectin and selectins[162, 163]. Indeed, circulating 
endothelin-1 levels are greater among PE patients[164].  Additionally, PE patients 
often present with activation of the coagulation pathway, resulting in 
microthrombi, and thus contributing to an impaired organ perfusion and 
endothelial dysfunction[165]. Additionally, the endothelium will acquire new 
properties, including the ability to produce vasoconstrictors and pro-coagulants 
like endothelin-1 and thromboxane A2, respectively, further aggravating maternal 
symptoms[141, 164]. Endothelial dysfunction is present in many vascular beds, 
and consequently, it has the ability to mediate diffused organ damage, much like 
what is observed during PE. 
 
Inadequate trophoblastic invasion is believed to be critical for the initiation of PE, 
and as such, the placental vasculature is likely one of the first tissues affected. 
Indeed, the endothelial lining of the spiral arteries fails to undergo denudation or 
remodelling in PE, thus causing the superficial invasion of the maternal 
vasculature[9, 166-168]. This ultimately leads to placental hypoxia, as the vessels 
continue to respond to vasorestrictive substances, thereby diminishing placental 
blood flow. As mentioned previously, anti-angiogenic mediators are released form 
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the placenta into the circulation and cause systemic endothelial dysfunction by 
antagonizing VEGF and PlGF. Indeed, decreased levels of VEGF are reported 
with PE as a result of the increase in circulating sFlt-1[169, 170], although data are 
inconsistent as some have reported increased levels of VEGF[171, 172]. This 
discrepancy likely results from the existence of two distinct and publishable VEGF 
measures[173, 174]. In PE, because of the increase in sFlt-1, a decrease in free 
circulating VEGF concentrations is often detected. Groups measuring total VEGF 
concentrations may observe an increase in circulating VEGF, as a result of a 
compensatory mechanism to counter the higher levels of sFlt-1 normally observed 
during PE[171, 172]. Elevated levels of circulating VEGF have been linked to 
transient hypotension while inhibitors of VEGF have been shown to induce 
proteinuria and hypertension[175]. Similarly, sFlt-1 antagonizes VEGF, and thus 
reduces the free form of VEGF in the circulation. It is interesting to note the 
existence of placental derived syncytiotrophoblast microfragments (STBM) in the 
maternal circulation[176], that appear as a result of necrosis, that may be involved 
in mediating endothelial cell injury by stimulating an exaggerated maternal 
inflammatory response. 
Circulating components are implicated in promoting endothelial cell activation and 
thus dysfunction in PE. A whole slew of mediators have been identified, some of 
which have been mentioned previously, including angiogenic mediators.  
Inflammatory mediators and plasma factors, like TNF and AngII, are commonly 
increased in PE[176-178]. As mentioned previously, there is an absence of 
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refractoriness to AngII in PE patients compared to normal pregnant controls[179]. 
Downstream signalling of AngII includes NADPH oxidase activation (which 
induces oxidative damage), TNF production and sFlt-1 secretion, all of which 
contribute to endothelial dysfunction[145, 180]. As a results of the increase 
placental hypoxia and ischemia, concentrations of inflammatory cytokines, like 
TNF, have been reported to be greater in PE compared to normal 
pregnancy[181]. Interestingly, in the circulation, TNFimpairs endothelium 
relaxation[182] via activation of NADPH oxidase[183] and negatively impacts NO 
signalling and may stimulate the production of endothelin-1[184], further 
demonstrating the ability of TNF to promote endothelial dysfunction by several 
means.  
Alternately, diminished response to vasodilatory substances, like prostaglandins, 
NO, acetylcholine and bradykinin has been reported[185-188]. Diminished PGI2 
production has also been observed in preeclamptic women[189]. An abnormal 
vasodilatory response can even be observed prior to the onset of clinical 
symptoms[36, 187, 190, 191]. Lower flow-mediated dilation and asymmetric 
dimethylarginine (endogenous inhibitor of eNOS) were observed in women that 
went on to develop PE, when compared to those with normal pregnancy[36, 191].  
 
For a summary of the circulating factors present in pregnancy and preeclampsia, 
see table 2. 
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Table 2 - Circulating factors in pregnancy and preeclampsia 
Circulating factor Pregnancy PE 
AngII  with  sensitivity  with  sensitivity 
Endothelin-1  with  sensitivity  with  sensitivity 
NO  
,  or = 
 response 
PGI2   with  response 
sFlt-1/sEng Low/absent  
STBM Low/absent  
Thromboxane A2   
TNF   
VEGF (free ligand)   
VEGF (total ligand)  
 
3.3.3 Oxidative stress 
Oxidative stress is implicated in a number of pathologies, including hypertension 
and obesity. It is the result of an imbalance between reactive oxygen species 
(ROS) production and the body’s ability to ward them off, via antioxidant defenses 
such as superoxide dismutase (SOD), catalase and glutathione peroxidase (GPx). 
ROS are critical for many biological processes, including normal pregnancy. For 
example, maternal vascular remodeling within the placenta is mediated by ROS, as 
is fetal growth and development[192]. Conversely, overactivation of NADPH 
oxidase is observed in PE patients, which contributes to the production of 
endothelial dysfunction and an exaggerated state of oxidative stress[193]. Indeed, 
circulating ROS, like superoxide anion, hydrogen peroxide and hydroxyl free 
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radicals directly and indirectly play a role in the induction of endothelial 
dysfunction[194]. For instance, they induce lipid peroxidation of the membrane 
bilayer of endothelial cells and promote oxidation of lipoproteins. Compromising 
the integrity of the bilayer and the functioning of signaling proteins at the 
membrane jeopardizes the proper functioning of the cell. Very high levels of lipid 
peroxidation, originating from the placenta, are observed in the circulation of 
women who go on to suffer from PE, thereby revealing the placenta as a point of 
origin for the production of oxidative damage[195, 196]. Indirectly, ROS scavenge 
NO, thereby minimizing NO stores, and blunting vasodilatory response[197, 198].  
In addition, studies have reported that antioxidant defenses are compromised in 
PE, as seen by a decrease in SOD, GPx and catalase in erythrocytes hemolysates 
and at the mRNA level in the placenta[45, 199-201]. Moreover, placental ROS 
levels were found to be elevated in an animal model of spontaneous PE (BPH/5 
mice), implicating this system in the production of placental alterations[202]. This 
increase was associated with a decrease in placental murine SOD expression. In 
PE, the placental vasculature is also laden with nitrotyrosine, an oxidative bi-
product[203]. Oxidative damage observed in PE is proposed to originate as a result 
of the inadequate placental perfusion and development[204].  
 
3.3.4 Renin-angiotensin system 
The RAS is an important mediator in the control of AP and sodium and water 
handling. Normal pregnancy is associated with cardiovascular and hemodynamic 
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changes that are mediated by different RAS components. As described above, 
abnormalities in the RAS are associated with PE (see diagram of the intricate RAS 
in Figure 2).  
Normal pregnancy is associated with an increase in circulating levels of AngII, 
along with a diminished sensitivity of the AT1R for its ligand[23]. Paradoxically, 
AngII levels are diminished while maternal sensitivity to this vasoactive substance 
is increased during PE[205]. A proposed mechanism for this effect is the 4-5 times 
increase in bradykinin 2 receptors density on platelets and placental omental 
vessels, compared to healthy pregnancy[206]. Indeed, these can form a 
heterodimer with the AT1R, which produces an increased sensitivity to 
AngII[206]. In addition, AT1 auto-antibodies (AT1-AA) have recently been found 
in the circulation of preeclamptic women[207]. These have a high affinity for the 
AT1 receptor. As such, AT1-AA and AngII both can stimulate the downstream 
signalling pathways of the AT1R, which include oxidative stress, endothelial 
dysfunction[208], sFlt-1 secretion and vasoconstriction[209]. Furthermore, the 
effects of AngII and AT1-AA appear to be additive[210].  
As previously mentioned, ACE2 and Ang-(1-7) are involved in AP regulation 
during pregnancy. ACE2 converts AngII, a vasoconstrictor, into the Ang-(-1-7), a 
vasodilator. Modulation of these RAS components may contribute to PE. Indeed, 
circulating Ang-(1-7) are decreased in preeclamptic women, compared to women 
with uncomplicated pregnancy[211]. The same group later observed a reduction in 
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ACE2 mRNA expression and Ang-(1-7) in the uterus of an animal model of PE. 
Lower levels of Ang-(1-7) likely contribute to the hypertensive state of PE[212]. 
A diminished level of circulating IRAP has also been observed during PE, 
compared to normal pregnancy[56]. This is potentially as a result of the necrosis of 
placental syncytiotrophoblasts, which normally synthesize IRAP during 
pregnancy[56]. IRAP is critical for glucose uptake and its decrease may be 
implicated in mediating hyperglycemia and insulin intolerance in PE[213, 214]. In 
addition, as IRAP is responsible for the degradation of OT, AngIII and arginine 
vasopressin[54, 55], its decreased circulating levels during PE may thus contribute 
to the associated vasoconstrictive state and may be involved in inducing 
pathological cardiac hypertrophy.  
 
3.3.5 Inflammation and immunity 
The fetus is analogous to an allograft in the woman’s womb. In order to prevent 
rejection, the mother’s immune system must adapt. As such, there is a shift away 
from cell mediated immunity (Th1) towards a humoral one (Th2), in addition to a 
diminished adaptive immune response[7]. Towards the end of pregnancy, a shift 
back towards cell-mediated immunity occurs in order to induce the timely delivery 
of the fetus[7]. Unfortunately, in the case of PE, cell-mediated immunity 
dominates throughout the pregnancy, resulting in an altered cytokine expression 
pattern[7], where pro-inflammatory cytokines, such as the tumor necrosis factor 
alpha (TNFα), interferon gamma (IFN-) and several interleukins (IL) show 
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enhanced expression[215]. This can have deleterious effects on endothelial 
function, the coagulation pathway and can modulate the production of ROS[216]. 
 
Many cells are involved in the PE mediated inflammatory response, among them, 
are endothelial cells. Not only do they respond to inflammatory mediators, but 
they themselves can secrete cytokines, ROS and vasoconstrictors, and up-regulate 
adhesion molecules to in turn recruit leukocytes. Because of their abundance 
throughout the body, local inflammatory responses can be propagated to distant 
locations. These inflammatory responses prompt endothelial dysfunction by i) 
promoting oxidative damage, ii) activating the coagulation pathway and iii) 
inducing the production of vasoconstrictors (AngII and endothelin-1) and surface 
adhesion molecules, and thus contribute to the pathophysiology of PE[119, 120, 
217]. 
 
Natural killer (NK) cells and monocytes may also play a role in PE initiation and 
progression. Indeed, NK cells are involved in immune recognition. They have the 
ability to recognize invasive cytotrophoblasts via killer-cell immunoglobulin-like 
receptors (KIR) and in turn mediate spiral artery remodeling. Insufficient NK cell 
activation may thus prevent adequate arterial remodeling and as a result, contribute 
to placental alterations[218-220]. PE patients often express inhibitory KIR, and as 
such, their NK and monocytes responses are often abnormal. This abnormal 
immune response is postulated to be a disease-promoting entity, which leads to 
inflammation via the production of type 1 cytokines[215]. 
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Placental hypoxia, often observed in PE, also leads to, induction of HIF-1[17]. 
Among the downstream mediators of HIF-1 is the activation of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-B), which is intimately 
involved in many inflammatory responses[215].  
In addition, an increase in circulating levels of syncytiotrophoblastic 
microfragments, or STBM, is often observed during PE[176]. These fragments are 
phagocytosed by macrophages and dendritic cells. Exposure of endothelial cells in 
vitro to STBM originating from preeclamptic women interfered with endothelial 
cell proliferation suggesting that these microfragments may be involved in 
mediating PE-associated endothelial damage[221]. These microparticles also cause 
the release of pro-inflammatory mediators by the endothelium, causing further 
damage[221, 222]. Neutrophils are induced by STBM to produce superoxide 
radicals in preeclamptic women, which also contribute to endothelial dysfunction 
and inflammation[223]. 
 
Although there appears to be several processes involved in the disease, there is 
likely considerable overlap, and identifying which is the initiator will prove to be 
difficult. Nevertheless, understanding the mechanisms implicated in its 
development are indispensable to identify treatment opportunities and reducing the 
significant risk of future cardiovascular and cardiometabolic diseases in women 
who have suffered from PE. 
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Chapter 4 - Exercise training  
4.1 Exercise training benefits for non-pregnant individuals 
Exercise has long been considered the ultimate means for preventing and treating 
CVD as it improves cardiac function and lowers AP[224]. Moreover, it improves 
an individual’s lipid profile and insulin sensitivity as well as preserves muscle 
mass[225]. In addition, it has been shown to promote mental, psychological and 
emotional health by diminishing anxiety and improving mood state and self-
esteem[226]. The wide range of beneficial effects produced by exercise is a result 
of its ability to affect most bodily systems, in addition to targeting the 
endothelium. For example, the shear stress resulting from exercise training 
minimizes plaque buildup and thus reduces the risk of developing 
atherosclerosis[227]. Moreover, exercise induces a physiological cardiac 
hypertrophy and promotes peripheral muscle development and strength; the heart 
and skeletal muscle both being tissues that necessitate vascular adaptations to 
ensure an adequate delivery of oxygen and nutrients[228]. Exercise promotes 
angiogenesis by mobilizing progenitor endothelial cells[228]. It also improves the 
vasculature’s vasodilatory capabilities by increasing eNOS expression and by 
enhancing the endothelium’s sensitivity to vasodilators[229, 230].   This increase 
in eNOS thus enhances the production of the vasodilatory NO[231]. Additionally, 
sensitivity to vasoconstrictors, like endothelin-1, is diminished, likely via a post-
receptor mechanism[228]. Through these mechanisms, an individual’s risk of 
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becoming hypertensive and developing associated-diseases are also greatly 
diminished[232].  
Better vasodilation and perfusion of the heart tissue following a myocardial infarct 
reduces the risk of cardiovascular mortality and fatal reinfarction[233]. In addition, 
animal studies investigating the effect of exercise training have demonstrated that 
it could decrease the size of the infarct. It has been suggested that this was as a 
result of an upregulation of cardiac KATP receptors[234]. Indeed, these potassium 
channels have the ability to control the length of the action potential by allowing 
potassium ions to leave the cell, which causes a hyperpolarization and makes it 
harder for the cell to reach its threshold voltage. KATP activation therefore prevents 
calcium-overload, thereby promoting cell survival and diminishing ischemic 
injury, resulting in smaller infarct size[235, 236]. In addition, in coronary vessels, 
KATP inactivation diminishes coronary blood flow, suggesting that KATP contribute 
to the exercise-induced vasodilation[237]. This enhanced blood flow may be 
explained by a better management of intracellular calcium concentrations[238].  It 
has been suggested that this mechanism may also be implicated in the beneficial 
effects of exercise training on AP control. Indeed, calcium channel blockers are 
already being used as antihypertensive medication[239].  
 
An increase in NO is among the beneficial impacts of exercise training as it 
decreases vascular tone. Moreover, it does not lead to the production of reactive 
nitrogen species (RNS)[240] as exercise also stimulates antioxidant defences in the 
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vasculature[228]. Similarly, SOD and GPx concentrations in skeletal muscle, and 
glutathione (GSH) in the liver are increased following exercise training[83]. 
Further supporting this is the observation that circulating lipid peroxides are also 
diminished with exercise training, due to an improved scavenging ability by the 
body’s antioxidant defences[241]. Thus, this increased antioxidant defense 
decreases ROS, making NO more available to produce vasodilation. In addition, 
an increase in the number of mitochondria in skeletal muscles is also observed 
with exercise training, possibly rendering the body more resilient to oxidative 
damage, as each mitochondrion has a reduced oxidative load[242, 243]. Also, 
exercise reduces the oxidative capacity of iron by increasing iron’s binding 
capacity to apotransferrin, thereby shrinking the iron labile pool[244]. Indeed, 
ferrous iron can have deleterious effects as it can catalyze the Fenton reaction, 
thereby generating ROS.  
 
Although acute bouts of exercise are known to be pro-inflammatory and induce 
oxidative stress, regular aerobic exercise has been shown to have anti-
inflammatory effects[245-247]. Indeed, long-term adherence to an exercise 
program leads to an increase in IL-6, which subsequently stimulates the release of 
IL-10 and IL-1RA (Interleukin-1 receptor antagonist), which are anti-
inflammatory cytokines, and inhibits TNF-α production[248]. Platelet-related 
inflammatory mediators, like P-selectin and soluble CD40 ligand, have also been 
found to be reduced following regular exercise training[249]. As such, chronic 
  
43 
exercise is recommended to patients with heart failure for these anti-inflammatory 
effects, [249].  
In addition, exercise can reverse endothelial damage that develops following an 
inflammatory response, as highlighted by the reduction in markers of endothelial 
dysfunction, like soluble vascular cell adhesion molecule-1 and monocyte 
chemoattractant protein-1 found among patients with CVD following exercise 
training[250]. In addition, chronic exercise diminishes the expression of 
circulating Toll-like receptors (TLR), which are involved in innate immune 
responses[251]. Downstream signaling pathways stimulated by the binding of 
lipopolysaccharide to the TLR were also decreased in skeletal muscle with 
exercise training, as were inflammatory cytokines, like TNF-α[251]. As such, this 
may by implicated in anti-inflammatory effects of exercise training.    
 
Exercise also upregulates the production of heat shock proteins (HSP), which are 
cytoprotective chaperones that ensure the proper transport and folding of proteins, 
and the removal of malfunctioning proteins[252]. Higher levels of HSP70, which 
have anti-apoptotic effects, have been observed in heart tissues with exercise 
training[253, 254]. It is interesting to note that higher levels of cardiac heat shock 
proteins correlate with an improved LV pressure recuperation following an 
ischemic episode[253]. HSPs may also be implicated in the reduction in TLR4 
observed with exercise training[251]. 
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The RAS is heavily involved in AP control, and dysregulation of this system has 
been implicated in several diseases[25]. Exercise training may modulate the RAS 
components in healthy individuals, however to date, much of the focus has been 
on investigating the effects in animal models and patients with CVD. For example, 
in the paraventricular nucleus and rostral ventrolateral medulla of spontaneously 
hypertensive rats (SHR), a significant increase in MasR and ACE2, along with a 
significant reduction in ACE and AT1R protein has been observed with chronic 
exercise[255]. An increase in Ang-(1-7) and its receptor have also been reported in 
the heart of SHR, while an rise in MasR could be observed in the aorta (Ang-(1-7) 
was not investigated), with exercise training[256, 257]. Additionally, exercise is 
reported to benefit the heart via a reduction in cardiac ACE activity and AngII 
levels in an animal model of heart failure[258].  
Circulating RAS components are also modulated by exercise training. Circulating 
renin, ACE, AngII and aldosterone were all decreased in rats who trained post-
myocardial infarction, compared to their sedentary counterparts, which was 
associated with a reduced LV end-systolic diameter (LVESD) and improved 
fractional shortening (FS)[259].  
 
4.2 Exercise training and pregnancy 
The American College of Obstetrics and Gynecology(ACOG) recommends at least 
30 minutes of moderate intensity exercise daily for healthy pregnant women[260] 
while the Canadian Society for Exercise Physiology (CSEP) and the Society of 
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Obstetricians and Gynaecologists of Canada (SOGC) recommend at least 30 
minutes of aerobic exercise, 4 days a week[261]. Of course, sports that may cause 
trauma, such as alpine skiing or hockey, are not recommended whereas 
recommended activities include, but are not limited to, aerobics, jogging, 
swimming and Pilates[260]. Many beneficial cardiovascular adaptations ensue as a 
result of training during pregnancy, including an increased blood volume, SV and 
CO, and diminished HR and TPR, when compared to their sedentary 
counterparts[103, 262]. Additionally, the risk of gestational diseases, including 
diabetes, insulin resistance and possibly hypertension, is diminished with exercise 
training[105, 114, 263]. Some of these benefits may be related to exercise 
training’s ability to limit gestational weight gain. It is important to note however 
that fetal growth and development are not known to be compromised[103].  
The benefits of exercise training during pregnancy can also be observed at both the 
fetal and placental level. Indeed, active women are reported to have both a greater 
total placental (462±18 vs. 414±14 cm
3
, p=0.05) and fetal (3.75±0.08 vs. 
3.49±0.07 kg, p=0.05) weight, accompanied by a greater placental growth rate 
(26±2 vs. 21±1cm
3
/week, p=0.04) [264, 265]. Improved placental development is 
proposed to result from the short-lived hypoxic environment that is thought to be 
produced by bouts of exercise which divert blood away from the placenta and 
towards the exercising muscles and for skin heat dissipation[266], while improved 
fetal development results from the placental effects mentioned here-in.  
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Additionally, the placentas of trained mothers have an improved functional 
volume (434±19 vs. 367±14 cm
3
, p=0.006), along with a diminished non-
functional tissue volume (28±4 vs. 45±6 cm
3
, p=0.04)[265]. Moreover, one study 
observed trophoblastic, stromal and endothelial cell proliferation to be greater 
among active women during normal pregnancy, with a proliferative index of 
45±14 mitoses/1000 nuclei vs. 29±10 mitoses/1000 nuclei, compared to their 
sedentary counterparts (p<0.008), allowing for an improved exchange between 
mother and fetus[267].  
Exercise training does not appear to have a detrimental effect on fetal birth 
weight[211], however a literature review by the Cochrane Collaboration has 
concluded that insufficient data exists to ascertain fetal benefits or risks[268]. 
Several studies have however observed a link between an increase in low fetal 
weight and exercise[211]. The smaller fetuses nevertheless had an enhanced lean 
body:fat mass ratio. A likely explanation for the discrepancy in the fetal weight 
data may be an inadequate nutritional intake on the part of the exercising mother. 
Indeed, exercising pregnant women require an increase in food consumption to 
compensate for the increased energy expenditure associated with exercise training. 
With adequate nutritional intake, exercise training does not appear to hinder fetal 
development, but rather promote it[211].   
 
Exercise training may also benefit endothelial function by altering angiogenic 
balance and circulating pro-inflammatory cytokines. Indeed, Weissgerber et al 
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have reported an increase in circulating PlGF [median (interquartile range): 278 
(221,647) vs. 268 (159,290) pg/mL, p=0.014] and a reduction in circulating sFlt-1 
[4217 (2014, 5481) vs. 5180 (4549, 5834) pg/mL, p=0.005] and sEng [7.8 (6.5, 
10.1) vs. 9.1 (7.7, 16.7) ng/ml, p=0.025] in late gestation compared to levels in 
sedentary counterparts[269]. A reduction in the anti-angiogenic factors sFlt-1 and 
sEng may suggest that placental development is closer to being accomplished 
when comparing trained versus sedentary women at the same time point. 
Additionally, Clapp et al observed a decrease in circulating TNF-α with exercise 
training, suggesting that exercise may also have anti-inflammatory effects during 
pregnancy[270].  
 
4.3 Exercise training and PE 
As mentioned previously, exercise training reduces the risk of developing CVD in 
a non-pregnant population. It stands to reason that exercise may also be beneficial 
for women at risk of PE.  
 
Many epidemiological studies are responsible for prompting the scientific 
community to investigate the impact of exercise training on gestational diseases. 
Exercise training has been reported to decrease the risk of developing gestational 
diabetes mellitus and gestational hypertension[271, 272] as well as been 
demonstrated to reduce PE risk[271, 273-281]. One of the first studies was carried 
out by Marcoux and colleagues in 1989 where they reported that women who 
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performed regular physical activity during the first 20 weeks of pregnancy had a 
43% reduction in the risk of developing PE compared to their sedentary 
counterparts[271]. Moreover, risk reduction was directly related to the amount of 
time spent exercising. In 2003, Sorensen et al. corroborated these results by 
showing that exercise during early pregnancy reduced the risk of PE by 35%[273]. 
Additionally, they found that training prior to and during gestation further reduced 
the risk of PE compared to inactive women. Similar results were again found by 
this group in women who exercised strenuously and to maximal exertion[275]. 
Indeed, in that study, the risk of PE was reduced by 48% and 78% in women 
categorized into the groups “moderate” and ”strenuous/maximal”, respectively, in 
comparison to the reference group (i.e. negligible/minimal physical exertion)[275].  
In 2004, Saftlas et al. published comparable results in which they observed a 
reduced PE prevalence, although non-significant, in pregnant women who engaged 
in any leisure-time activity during gestation compared to inactive women. 
However, unlike previous studies, this was independent of the level of caloric 
expenditure (i.e. amount of exercise)[274]. The small sample size (n=44), 
compared to those in previously mentioned studies (n=172[271] and n=201[273]), 
likely compromised the evaluation of the effect of exercise training on PE 
incidence in this study. More recently, Rudra et al. (2008) assessed prospectively 
the effect of exercise on PE risk by categorizing the subjects based on time spent 
exercising and energy expenditure (n=224 with PE)[281]. Although their results 
did not reach statistical significance, recreational activity in the year prior to 
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pregnancy, associated with or without gestational exercise training, correlated with 
a reduced risk of PE, compared to inactive women. Conversely, women who were 
active only during early pregnancy (n=83) tended to have an increased PE risk 
(n=9) compared to those who were sedentary before and during pregnancy 
although this was also not significant. The evaluation period for training consisted 
of only a single week prior to the prenatal visit, thereby biasing the exercise 
training evaluation. Furthermore, the sample size was again small (n=9) which 
somewhat undermines the conclusions that can be inferred from these results. 
Magnus et al. carried out a prospective study to examine the effect of recreational 
physical activity on the incidence of PE[276]. They too observed a beneficial 
effect/trend but only among non-obese women, and the extent of the protection 
was limited (20% reduction in risk). However, in this study, intensity and duration 
of the physical activity was not taken into consideration. As such, it is likely that 
obese women who exercised as often as the non-obese may have done so at lower 
intensities and for shorter bouts, which may explain the lack of effect observed in 
this group, particularly since others have demonstrated that exercise training 
benefits typically correlate with the intensity and duration of the activity[271, 273, 
275]. Hegaard et al. also found a non-significant reduction in PE risk among 
women with the highest degree of physical activity in the year prior to pregnancy, 
especially among overweight women[278]. However, this study failed to acquire 
information about gestational physical activity, which may have contributed to the 
non-significance of the physical activity effect reported, as women may have 
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stopped exercising during pregnancy and thus may not have obtained as much 
benefits. Tyldum’s study again found a non-significant lower risk of PE among 
women that trained 120 min/week previously to pregnancy but also failed to gather 
information about gestational exercise patterns[279]. Moreover, the exercise 
training information was obtained between 9 months and 20 years before 
pregnancy, and as such this data may not accurately reflect the activity profile of 
these subjects immediately prior to their pregnancies. Additionally, the reference 
or control group consisted of women who either never exercised or exercised less 
than once a week and as such, may not be completely sedentary and may mask a 
possible effect of training. Recently, Fortner et al. investigated prospectively the 
effect of pre-pregnancy and early pregnancy activity on PE risk[280]. The authors 
observed a non-significant lower risk of developing PE during early pregnancy 
with total activity. This study did not however observe an association between pre-
pregnancy total activity and PE risk, unlike previous studies. Again, a small 
sample size (30 preeclamptic women) may have prevented the detection of a link 
between PE risk and physical activity.  
 
Yeo et al. investigated the effect of stretching versus walking on PE risk[277]. 
They observed that stretching tended to reduce the risks of developing PE 
compared to pregnant walkers (2.6% vs. 14.6%, respectively) although these 
differences were not significant, likely due to sample size (n=41 and n=38 for 
walkers and stretchers respectively) [282]. However, it should be noted that 
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women in the walking group were also reported to work more hours per week. 
Hence, this may have caused an increased stress, which may have contributed to 
the increased prevalence of the disease as has been previously reported[88, 126, 
127]. In addition, one should be aware that in this study the exercise program 
began at 18 weeks of gestation in previously sedentary women who were at risk 
for PE. Hence, the mechanisms involved in the development of the disease may 
have already been initiated and more vigorous exercise at this time point may have 
accentuated the development of the disease while lower intensity exercise, such as 
stretching, may have prevented the disease by favouring antioxidant defences. 
Indeed, the authors found that the stretching group had significantly more 
circulating transferrin, an antioxidant marker, at the end of gestation compared to 
their walking counterparts. Interestingly, in Sorensen’s study, the small group of 
women who were previously inactive before pregnancy tended to have an 
increased risk for PE when exercise training was initiated at the beginning of 
pregnancy, although again, not reaching statistical significance[281]. Hence, this 
suggests that initiating an exercise program during mid-gestation, in previously 
sedentary women, may enhance the risk of PE.  
 
However, the observation that exercise reduces the risk of PE is not shared by all. 
Vollebregt et al found no protective effect of physical activity on PE risk[283]. 
Although this study did not find an association, their evaluation of physical 
activity was based on a short time-frame (1 week) prior to their first prenatal care 
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visit. This cannot be used as an adequate evaluation of gestational physical 
activity, and consequently, caution should be exerted regarding the study’s 
conclusions. Curiously, two studies found a deleterious effect of exercise on PE 
risk[281, 284]. As mentioned above, Rudra et al observed a non-significant 
increase in PE with exercise training in women initiating exercise during early 
pregnancy[281]. Because of the small number of cases however, no clear 
conclusion can be made. Although Osterdal found that exercise had no protective 
effect over PE prevalence, they did observe that women who did moderate 
exercise for more than 270 min/week during early pregnancy were at an increased 
risk of severe PE[284]. It is important to note that both Vollebregt and Osterdal’s 
studies included women with severe PE or SPE, respectively. These studies 
suggest that initiating physical activity at the beginning of pregnancy may be 
deleterious to women at risk of severe PE, such as those who are previously 
hypertensive, much like what is observed in Yeo et al.’s study[277]. Additionally, 
both studies investigated the effect of initiating physical activity on PE risk, unlike 
most previous studies. As such, the time at which exercise is initiated appears to 
play a primordial role in determining how exercise may modulate PE risk. 
 
Most of the studies investigating the effects of exercise prior to pregnancy 
observed either a significant[273, 275, 281, 283] or non-significant[278, 279] 
decrease in prevalence of PE. Limitations within the studies observing a non-
significant effect may have been responsible for reducing the detectable impacts of 
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exercise training on PE risk. For instance, the studies by Saftlas et al. and Fortner 
et al., did not observe a protective effect of pre-pregnancy activity on PE risk, 
possibly as a result of the small sample size, which may have lacked the statistical 
power to demonstrate this association.  
 
To date, exercise training has yet to be recommended in at-risk pregnancies even 
though retrospective studies have shown a positive link between exercise training 
and a decreased PE risk. These studies are considered insufficient as they were 
mainly observational in nature, they are not randomized studies and their samples 
sizes are too small[285]. Biases can result from such studies, and their results 
depend solely on the mother’ self-evaluation of her exercise pattern before and/or 
during pregnancy. There is thus no quantitative assessment of the amount of 
training performed by those enrolled in the studies. As such, large-scale studies 
will be required to determine the effect of exercise on PE risk, with specific 
attention to the time frame of initiation of exercise training as well as to the 
intensity and type of exercise prescribed. Indeed, a link between aerobic fitness 
and hypertension prevention has been observed[286].  
 
Recently, an animal study from our group was published demonstrating the 
benefits of exercise training in the prevention of PE-like features, lending support 
to the albeit inconclusive epidemiological findings mentioned above[287]. The use 
of an animal model allowed many parameters to be held constant, enabling us to 
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show the cause and effect relationship between exercise training and PE risk. The 
transgenic model used in this study consisted of female mice overexpressing 
human angiotensinogen (hANG), which upon mating with males overexpressing 
human renin (hREN) developed many PE-like features, including hypertension, 
proteinuria, cardiac hypertrophy, placental alterations and impaired vascular 
reactivity. To investigate the effect of exercise training, female hANG mice were 
placed in exercise cages with free access to a wheel 4 weeks prior to mating and 
were maintained within these cages for the length of their pregnancy. Interestingly, 
much like what is observed in women upon becoming pregnant, the pregnant 
female mice consistently diminished the amount of exercise performed, reaching a 
minimum 2-3 days prior to delivery. Exercise training prevented the development 
of proteinuria, pathological cardiac hypertrophy and placental alterations while 
their AP was no longer significantly different from their non-transgenic 
counterparts at the end of gestation. Moreover, there were no deleterious effects of 
exercise observed on the fetus, both in the normal and preeclamptic pregnancies, 
further supporting exercise as a preventive and possibly therapeutic option for PE. 
 
4.3.1 Potential mechanisms involved in the beneficial impact of exercise of PE 
Although exercise training appears to protect women from developing PE, very 
little is known regarding the mechanisms involved in these effects. Exercise 
training has been proposed to reduce PE risk by promoting placental growth and 
development, reducing oxidative damage, improving endothelial function, as well 
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as immune and inflammatory responses and modulating the RAS components, all 
of which could contribute to improving pregnancy outcome.  
 
Placental development. Normal placental growth and development requires fine 
modulation of oxygen tension. Thus the benefits of exercise training may lie 
primarily in its ability to ensure adequate placentation. Indeed, by temporarily 
creating a hypoxic environment, exercise promotes placental growth and 
development, and in doing so, minimizes the placental release of anti-angiogenic 
factors into the circulation, such as sFlt-1, ROS and pro-inflammatory mediators, 
such as TNF-α[10, 266, 269, 288, 289]. Further supporting the notion that exercise 
promotes adequate placental development, our group has demonstrated, using an 
animal model, that exercise training was associated with normalization of 
placental VEGF levels and prevention of PE-like features (i.e. placental 
alterations)[287]. In addition to the role of anti-angiogenic and pro-inflammatory 
mediators in PE, circulating factors, like AngII and endothelin-1 are heavily 
implicated in the development of the diffused endothelial cell damage observed 
during PE[177, 178].  
 
Oxidative stress. An imbalance between ROS production and antioxidant 
capacities has been observed in PE and has been proposed to be implicated in 
disease development[199]. As previously mentioned, training promotes 
antioxidant defences and reduces markers of oxidative stress, such as lipid 
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peroxide levels[83, 241, 290]. Chronic exercise is likely an important mechanism 
by protecting mothers from oxidative damage thereby reducing their risk of 
developing PE[199, 246].  
 
Endothelial function. PE is often characterized by systemic endothelial 
dysfunction. Exercise training has the potential to prevent and reverse the damage 
mediated by ROS and anti-inflammatory cytokines, as seen in non-pregnant 
individuals, and anti-angiogenic mediators, as is observed during normal 
pregnancy[248, 251, 269, 288]. Importantly, a decrease in these cytokines will 
consequently reduce the levels of endothelin-1, and thus diminish 
vasoconstriction[291]. Additionally, increased shear stress may also contribute to 
the benefits related to exercise training, as it induces endothelial cell proliferation 
and promotes eNOS and antioxidants expression[227]. Exercise training may 
reduce circulating levels of AngII, similar to what is observed in an animal model 
of myocardial infarction, and thus improve endothelial function[292]. Along 
similar lines, exercise training reduces plasma endothelin-1 in non-pregnant 
women[231, 293].  Analogous effects on AngII and endothelin-1 are proposed to 
arise during PE[231, 259]. Indeed, lowering circulating levels of these mediators 
will diminish their capacity to promote endothelial dysfunction. 
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Inflammation and immunity. Abnormal immune responses and inflammation have 
been implicated in the initiation of PE. Although very little is known concerning 
the effectiveness of exercise training during pregnancy and PE, it is proposed to 
stimulate anti-inflammatory responses and reverse inflammation-related 
endothelial cell injury, as alluded to previously.  
 
Renin-angiotensin system. RAS components are dysregulated in many CVD, 
including PE[22, 25]. The effect of exercise training on RAS components in PE 
has had limited exposure in the scientific community. Nevertheless, since PE is 
considered a CVD, exercise training is postulated to have similar effects in 
preeclamptic patients, as previously mentioned. MasR and ACE2 are proposed to 
increase while ACE and AT1R are postulated to decrease, with exercise training, 
much like what has been observed in hypertensive animal models[255]. The 
increase in ACE2 should yield higher levels of Ang-(1-7), as a result of AngII 
degradation[256, 257]. These effects are suspected to occur both in circulation and 
at the tissue level[256, 257, 259]. 
 
Many mechanisms are likely implicated in the protective effect of exercise 
training on PE, since it targets many pathways and systems. Some of these have 
yet to be investigated specifically during pregnancy and in women at risk of PE. 
Mechanistic studies, like those performed with animal models, are thus warranted 
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to better understand the effect of exercise training on PE risk, and should further 
shed light into the pathogenesis of PE. 
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Chapter 5: Objectives and Hypotheses 
 
Hypertension is an important risk factor for preeclampsia. Identifying possible 
preventive therapies or treatments are greatly needed, as to date, there is no cure 
for this disease, aside from fetal delivery. The purpose of this study is thus to 
investigate the effect of exercise training as a prophylactic measure to alleviate 
preeclampsia-like features in an animal model of preeclampsia superimposed on 
chronic hypertension. In addition, possible mechanisms involved in disease 
development will be investigated.  
 
Given that exercise training is currently an effective therapy for treating and 
preventing several cardiovascular diseases, including hypertension and heart 
failure, we hypothesize that it will prevent the development of superimposed 
preeclampsia in our animal model.  Furthermore, based on previously reported 
effects of exercise training on normal pregnancy, we suspect that it will have 
beneficial effects on placental development, and consequently, on maternal 
symptoms.
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Chapter 6: Novel role of the renin-angiotensin system in the beneficial effects of exercise 
on a preeclampsia model.  
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Abbreviation list 
 
ACE2: Angiotensin converting enzyme 2 
ACOG: American College of Obstetricians and Gynecologists  
ACR: Albumin/creatinine ratio  
AngII: Angiotensin II 
AP: Arterial pressure 
AT1R: Angiotensin II type 1 receptor 
BNP: Brain natriuretic protein 
EF: Ejection fraction  
ExT: Exercise training  
FS: Fractional shortening  
HR: Heart rate 
IUGR: Intra-uterine growth restriction 
IVS: Interventricular septum 
LV: Left ventricle 
LVD: Left ventricular diameter 
LVEDD:  Left ventricular diastolic volume  
LVEDV: Left ventricular end-diastolic volume 
LVESD: Left ventricular systolic volume. 
LVESV: Left ventricular end-systolic volumes.  
LVID: Left ventricular internal diameter 
LVPW: Left ventricular posterior wall thickness 
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MAP: Mean arterial pressure 
MasR: Angiotensin-(1-7) Mas oncogene receptor 
Nab1: NGFI-A binding protein 1 
NT: Non-transgenic 
PE: Preeclampsia  
S16: 40S ribosomal protein S16 
sFlt-1: Soluble Fms-like tyrosine kinase-1 
SPE: Preeclampsia superimposed on chronic hypertension 
VEGF: Vascular endothelial growth factor  
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Abstract  
 
Hypertension increases preeclampsia prevalence to 15-25%. Our aim is to investigate the 
protective role of exercise traininig (ExT) on pregnancy outcome in a mouse model of 
superimposed preeclampsia on chronic hypertension (SPE) as well as the implicated 
mechanisms in this effect.  
Transgenic female mice overexpressing human angiotensinogen and human renin were used 
as a model of SPE. Trained mothers were placed in cages with access to a running wheel 4 
weeks prior to mating, and remained within these cages throughout gestation. Blood pressure 
was measured by telemetry. Proteinuria and circulating soluble Fms-like tyrosine kinase-1 
(sFlt-1) were determined by ELISA.  
The blood pressure and proteinuria increase present in pregnant transgenic mice was markedly 
reduced with ExT whereas placental pathology was absent. Placental VEGF protein, sFlt-1 
mRNA, and circulating sFlt-1 were significantly increased in transgenic sedentary mice, while 
training normalized these markers. In addition, training normalized the significant increase in 
angiotensin II type 1 receptor and reduction in Angiotensin-(1-7) Mas receptor (MasR) 
observed in sedentary R
+
A
+ 
placenta. Also, reduced Aortic MasR and angiotensin converting-
enzyme 2 in sedentary R
+
A
+
 mice were increased with training.  
This study demonstrates the protective effects of ExT on SPE-like features in an animal model 
and involves the novel modulation of the renin-angiotensin system. 
 
Keywords: exercise training, superimposed preeclampsia on chronic hypertension, placental 
markers, renin-angiotensin system, angiogenic balance  
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Introduction 
Preeclampsia (PE) affects 5-7% of all pregnancies in the developed world and far more in 
developing countries. As such, it is among the leading causes of perinatal mortality and 
morbidity[1]. PE is diagnosed by the onset of hypertension and proteinuria after 20 weeks of 
gestation and can deteriorate to maternal end-organ damage and fetal death[2]. Chronic 
hypertension is an important risk factor for this pathology as 15-25% of hypertensive women 
develop superimposed PE on chronic hypertension (SPE) during their pregnancy. PE is a 
multifactorial disease arising from a complex combination of genetic and environmental 
factors, whose underlying molecular mechanisms are still poorly understood[1, 3, 4]. Delivery 
remains the only treatment option available to preeclamptic women[5]. Consequently, a high 
incidence of preterm delivery is associated with this disease[2].  
 
We have recently characterized a new animal model of SPE[6]. These mice overexpress both 
human angiotensinogen and renin (R
+
A
+
), and thus, are hypertensive at baseline. During their 
pregnancy, these mice develop SPE-like features as their blood pressure increases and they 
develop de novo proteinuria. This new model is especially useful as SPE is a clinical reality 
that affects many women and to our knowledge, it is the only model of its kind. Furthermore, 
it is particularly relevant as many studies are now pointing to the involvement of the renin-
angiotensin system in the development of PE. Indeed, many circulating RAS components are 
altered and sensitivity to angiotensin II (AngII) is increased during PE compared to normal 
pregnancy. Interestingly, auto-antibodies against the AngII type 1 receptor (AT1R) have been 
identified in the circulation of women destined to develop preeclampsia, which, along with 
AngII, can for instance, stimulate the secretion of soluble Fms-like tyrosine kinase-1 (sFlt-1). 
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This model therefore will permit a better understanding of the mechanisms involved in the 
development of SPE. Indeed, mice are an asset in mechanistic studies since experimental 
parameters can be held constant while trying to elucidate the cause and effect relationship 
between exercise training (ExT) and SPE-like features. Furthermore, mice share many 
physiological characteristics with that of a human pregnancy[7]. Importantly, both human and 
mouse pregnancies are characterized by a hemochorial placentation, a central component for 
the development of PE[8], and a decrease in blood pressure as a result of pregnancy[9, 10].  
 
The beneficial impact of ExT on the prevention and treatment of cardiovascular diseases has 
been well documented in men and non-pregnant women[11]. Physical activity has also been 
suggested to be beneficial during normal pregnancy by improving maternal cardiovascular and 
metabolic adaptations as well as placental and fetal development[12]. Furthermore, it has been 
shown to reduce the incidence of gestational diseases such as PE and gestational diabetes[13]. 
However, for PE, drawing conclusions on the effect of exercise on pregnancy is made difficult 
by the low number of studies, which are largely observational, and their small sample 
sizes[14]. Although guidelines from the American College of Obstetricians and Gynecologists 
(ACOG) recommend that pregnant women participate in moderate intensity exercise on most, 
if not all days of the week during their pregnancy[15], this does not apply to women at risk of 
complications given the lack of data, even though they may benefit from regular physical 
activity. Conversely, we have recently demonstrated in a mouse model of PE that ExT both 
before and during pregnancy can markedly reduce PE-like features[16]. Moreover, our data 
suggests that normalization of placental development and angiogenic balance may be 
implicated in the effects of ExT. Given this and the numerous human studies which support 
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the beneficial effects of physical activity, more research is warranted to eventually modify the 
present ACOG guidelines. Therefore, the aim of this study is to determine if SPE-like features 
can be alleviated or normalized by ExT in R
+
A
+
 mice. 
 
Results 
 
Similar exercise patterns were observed in both R
+
A
+
 and R
-
A
-
 trained mice prior to and 
during pregnancy (Figure S1; see online supplement). The distance travelled daily diminished 
drastically at day 1 of gestation and continued to steadily decrease as pregnancy progressed in 
both groups, reaching a minimum around night 18 of gestation. Furthermore, there was no 
effect of ExT or genotype on length of gestation, baseline bodyweight and gestational weight 
gain (Table S2; please see online supplement).  
As shown previously, R
+
A
+
 mice were hypertensive at baseline (136.62 vs. 98.91 mmHg in 
R
+
A
+
 and non-transgenic respectively, p< 0.001), and consequently blood pressure was 
significantly higher than their non-transgenic littermates prior to and throughout gestation 
(data not shown). Sedentary R
+
A
+
 mice experienced a further increase in blood pressure at the 
end of pregnancy, which was prevented by ExT (Figure 1A). Proteinuria, assessed by the 
albumin/creatinine ratio (ACR), was significantly increased in R
+
A
+
 compared to their non-
transgenic littermates and was significantly increased with gestation in (Figure 1B). 
Conversely, trained R
+
A
+
 had significantly lower levels of ACR although these values were 
not completely normalised (Figure 1B).  
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As reported previously, cardiac hypertrophy, characterized by elevated ventricular mass, was 
observed in R
+
A
+
 at the end of gestation, but was unaffected by training (Table 1). 
Interestingly, the right atrium had a significantly increased mass in trained mice independently 
of genotype whereas the right ventricle was also significantly enlarged by ExT but only in 
non-transgenic mice. Nab1, a marker of left ventricular dysfunction, was found to be increased 
in the transgenic mice, as reported previously, while ExT caused a significant reduction, these 
values were not completely normalized (Figure 2A). Although the marker of pathological 
cardiac hypertrophy, BNP, was not significantly increased in R
+
A
+
 mice, a significant 
reduction in BNP was observed with ExT, independent of genotype (Figure 2B). 
Echocardiographic analysis demonstrated similar trends, where ejection fraction and fractional 
shortening were significantly decreased in R
+
A
+
 and tended to be increased with ExT but this 
was not significant (Tables S3 and S4; please see online supplement). 
 
As previously published, sedentary R
+
A
+ 
mice presented with an evident placental pathology 
in comparison to their non-transgenic littermates (Table 2). This was characterized by a 
significant increase in hyalinization, giant cell island loss and loss of labyrinthine structure. 
These alterations were supported by our immunohistochemistry results demonstrating a 
significant increase in placental cytokeratin and histone H3 staining in placentas from our 
sedentary transgenic mothers (Figures S2 and S3, please see online supplement). Importantly, 
all these placental parameters were completely normalized with ExT (Table 2 and Figures S2 
and S3). This had a functional impact as it translated into a normalization of total fetal and 
placental weight as well as litter size with ExT in R
+
A
+
 (Table 3). Indeed, sedentary transgenic 
mice had decreased placental weight and an increased prevalence of IUGR, in addition to 
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smaller litters compared to non-transgenic controls. Lower placental weight is likely 
responsible for the IUGR observed. Interestingly, we also observed an increase in 
fetal:placental weight ratio(Table 3) with ExT independently of genotype suggesting an 
improved placental function, even in non-transgenic animals.   
 
Placental VEGF protein was significantly increased in the sedentary transgenic mice 
compared to their sedentary controls, whereas this was attenuated with ExT (Figure 3A). 
Placental sFlt-1 mRNA was also significantly increased in sedentary R
+
A
+ 
mice compared to 
non-transgenic littermates but was completely normalized by ExT (Figure 3B). A similar 
pattern was observed in the circulation, where circulating sFlt-1 levels were found to be 
increased in the sedentary transgenic group compared to their non-transgenic controls, but 
these differences were absent in the trained mice (Figure 3C). As such, the decreased placental 
sFlt-1 transcription in trained R
+
A
+
 mice is likely responsible for the reduced circulating sFlt-1 
levels observed in this study. 
 
Placental AT1R protein was significantly increased while that of the placental MasR and 
ACE2 were diminished in the sedentary R
+
A
+
 mice compared to non-transgenic littermates 
(Figure 4). Interestingly, ExT normalized both AT1R and Mas receptor expression whereas 
ACE2 was unaffected by training. In addition, ExT also reduced AT1R in non-transgenic 
controls. RAS components were also studied in the mouse aorta (Figure 5), to investigate 
potential mechanisms implicated in blood pressure regulation.  Similarly to what we observed 
in the placenta, aortic AT1R was significantly increased while the MasR and ACE2 were 
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diminished in the aortas of R
+
A
+
 mice. In contrast, ExT caused an increase only in the MasR 
while it had no effect of AT1 and ACE2.  
Circulating glucose was also examined in our animal model, as diabetes is a known risk factor 
for preeclampsia. Although no effect of genotype could be observed on circulating glucose 
levels, exercise did cause a significant reduction (Figure S4; please see online supplement) as 
has been previously observed by others[17]. 
 
Discussion 
 
In our study, R
+
A
+
 mice developed many SPE-like features, including an increase in blood 
pressure, proteinuria, placental alterations and IUGR as previously reported[18]. However, 
ExT before and during gestation in these mice normalized all of these features with the 
exception of proteinuria which was reduced but not to the levels of control mice. This strongly 
supports the beneficial effect of this ExT regimen on SPE features and is in line with the 
numerous retrospective studies which have demonstrated a protective effect on PE in 
women[14]. Moreover, our data implicates a novel modulation of the RAS and angiogenic 
balance by both the disease and ExT.  For instance, we observed an increase in both ACE2 
and MasR expression in aortic extracts with ExT which may contribute to promoting healthy 
endothelial function. Indeed, ACE2 converts AngII into Ang-(1-7), a peptide whose effects 
opposes those of AngII while the MasR is the receptor that transduces the Ang-(1-7) 
signal[19]. As such, the observed increase in both ACE2 and MasR in the vasculature with 
ExT could contribute to minimize the AngII-associated vasoconstriction which is often 
exaggerated in PE. This is line with reports that have demonstrated a stimulation of the Ang-
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(1-7) axis with ExT looking at cardiac ACE2 which has been suggested to contribute to the 
physiological cardiac hypertrophy associated with this type of ExT as well as to prevent 
ventricular dysfunction in a heart failure mouse model[20]. Increased MasR has also been 
reported in hearts[21] and aortas[22] of spontaneously hypertensive rats (SHR) rats with ExT.  
In our study, ExT may improve endothelial function during pregnancy not only by altering 
RAS components, but by diminishing circulating levels of glucose and by promoting 
angiogenic balance. For instance, the ExT normalization of placental sFlt-1 mRNA expression 
and circulating levels of this anti-angiogenic factor may promote adequate endothelial 
response. Indeed, circulating sFlt-1 has been shown to antagonize circulating levels of VEGF 
and placental growth factor, and in doing so promotes endothelial dysfunction. Moreover, as 
high levels of sFlt-1 are known to inhibit trophoblastic invasion, training-induced decreases in 
sFlt-1 may also favour placental development.  
Consequently, the increased sFlt-1 levels observed in our sedentary R
+
A
+ 
mice may contribute 
to the development of several SPE-like features observed in our model. Indeed, much like 
women who suffer from PE[23], our sedentary R
+
A
+
 dams presented with a significant 
increase in circulating sFlt-1 and placental sFlt-1 mRNA expression. This is in line with the 
hypothesis that PE is associated with an anti-angiogenic shift that is initiated in the placenta.  
Interestingly, our sedentary transgenic mice also had a significant increase in placental VEGF 
protein expression, which was reduced with training. Normal pregnancy is characterized by an 
increase in angiogenic factors, such as VEGF, at the start of pregnancy which usually decrease 
as pregnancy progresses and placental development nears completion. The presence of high 
VEGF levels at the end of gestation in our model may result from the inadequate placental 
development that is present. As such, in response to hypoxia, increased VEGF levels may be 
 72 
aimed at stimulating adequate placental vascularization. Alternatively, this increase may occur 
to counter-balance the increase in sFlt-1 associated with our SPE model.  
 
Placental alterations observed in sedentary R
+
A
+
 mice were completely normalized by ExT. 
This was further characterized by normalization, in trained transgenic females, of placental 
immunostaining to histone H3 and cytokeratin, which are markers of mitosis and trophoblastic 
cells in all phases respectively, which were found to be increased in sedentary transgenic mice. 
These increased placental markers in conjunction with the increase in labyrinthine structure 
loss observed by histology, support the premise that trophoblasts in R
+
A
+
 placentas are highly 
proliferative and fail to differentiate. This is in line with studies which suggest that PE is 
produced not only by an inadequate trophoblastic invasion, but also by a highly proliferative 
and underdeveloped placenta[24]. As such, our data further supports this hypothesis and 
suggests that our SPE model truly represents a clinical reality. On the other hand, the 
cytokeratin and histone H3 results support the hypothesis that ExT promotes healthy placental 
development by increasing placental villous trophoblastic volume and enhancing the exchange 
of nutrients and oxygen towards the growing fetus. As such, we observed an increase in the 
ratio of fetal to placental weight with ExT suggesting an improved placental function. In 
addition, fetal weight and litter size were completely normalized in trained R
+
A
+
 females 
suggesting these placental modifications had a functional impact on fetal development. Hence, 
it is clear that ExT both before and during gestation can be very beneficial to fetal outcome in 
mice. 
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In addition to the effects of ExT on the aortic RAS components, local placental RAS was also 
modified. Indeed, our sedentary R
+
A
+
 mice had a significant increase in AT1R, which was 
completely normalized with ExT. AngII, via the AT1R, is known to induce the production and 
secretion of sFlt-1, along with mediating oxidative stress, inflammation and 
vasoconstriction[25-27]. As such, the exercise-induced reduction in AT1R may be responsible 
for the decrease in both placental sFlt-1 mRNA and circulating sFlt-1 but may also contribute 
to improving many of the SPE-associated features by this mechanism. Similar AT1R 
reductions with ExT have been observed in other tissues, such as the paraventricular nucleus 
and rostral ventrolateral medulla, in SHR rats[28]. Moroever, the significant reduction in 
placental MasR observed in the R
+
A
+
 sedentary mothers was completely normalized by ExT. 
This may therefore enhance the Ang-(1-7) mediated vasodilation pathway and minimize under 
perfusion of the placenta. Conversely, placental ACE2 was found to be decreased in our 
mouse model with no significant effect of ExT. In line with our results, decreased placental 
ACE2 has been suggested to be implicated in the development of IUGR, for instance with 
maternal protein-restriction[29] and in a rat model of PE[30]. Indeed, it is proposed that the 
resulting reduction in placental Ang-(1-7) decreases local vasodilation and thus impedes 
placental-fetal blood flow.  The effect of ExT on the MasR may thus not only be beneficial for 
PE but also other conditions which are at risk of IUGR. 
 
As previously reported, sedentary R
+
A
+
 mice develop pathological cardiac hypertrophy 
compared to the non-transgenic mice. Although ExT did not have any effect on heart weight, 
modifications in cardiac pathological markers could be observed suggesting that there may be 
modifications in the type of hypertrophy present in trained transgenic mice. Indeed, Nab1 and 
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BNP were both significantly decreased with ExT in transgenic dams although Nab1 was not 
completely normalized. Fractional shortening and ejection fraction were significantly 
compromised in the sedentary R
+
A
+
 mice while ExT tended to increase these parameters but 
did not reach significance. Given that the blood pressure in R
+
A
+
 mice is not reduced below 
baseline with ExT, it is not very surprising that ventricular function is not markedly 
ameliorated although cardiac markers suggest that there may be a slight improvement. 
 
Cages with free access to an exercise wheel were used to investigate the effect of training in 
SPE prevention in our study. Of note, the degree of training observed in our mice corresponds 
to what is reported in the literature[31-33] and did not vary according to genotype. Three 
weeks of free wheel training is associated with many cardiovascular benefits in non-pregnant 
rodents, including an increase in VO2max[34-36]. As similar improvements are observed in 
non-pregnant women following a moderate aerobic ExT regimen[37, 38], we suspect that the 
beneficial effects of this type of ExT on pregnancy outcome in our mouse model may also 
translate to pregnant women. This would be in line with the well-known use of ExT as an 
effective therapy for preventing and treating many cardiovascular diseases in non-pregnant 
patients[39]. 
 
This study has advanced our understanding of the role of ExT in the prevention of many 
hallmark features of PE. ExT attenuated many of the SPE-associated features in our animal 
model, including the rise in blood pressure and proteinuria, placental alterations and IUGR. 
Preeclampsia is suspected to arise due to abnormalities in placentation, either as a result of an 
inadequate trophoblast invasion or hyperproliferation, which gives rise to the release of anti-
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angiogenic factors into the circulation. We propose that ExT restores angiogenic balance by 
rehabilitating the placental milieu, and in doing so, promotes placental development. 
Therefore, the healthy placenta no longer releases anti-angiogenic mediators which would 
favour endothelial dysfunction. Additionally, modulation of the RAS may be implicated in the 
ExT SPE risk reduction by minimizing the effects of Angiotensin II via modulation of AT1R 
but also by stimulating the Ang-(1-7) pathway. This preventive and therapeutic approach, if 
proven effective, could minimize the prevalence of future cardiovascular diseases, deficits 
associated with preterm births, and perinatal mortality and morbidity. Indeed, in contrast to 
pharmacological treatments inhibiting the RAS which are teratogenic, ExT may efficiently 
modulate this system to obtain the required benefits such as decreased blood pressure and 
improved placental development without the adverse fetal effects. However, large-scale 
randomized studies are needed to confirm these effects in women and eventually lead to 
modifications of the ACOG guidelines, which presently do not support the prescription of ExT 
to women at risk of gestational complications. 
 
Materials and Methods 
 
Animals. R
+
A
+
 transgenic mice were produced by breeding heterozygous human renin mice (Ren9 
line)[40] with heterozygous human angiotensinogen mice (204/1 line)[41]. Both single transgenic lines 
were a generous gift from Dr. Curt D. Sigmund of the University of Iowa, and were maintained in our 
animal facility by backcrossing with C57BL/6 mice (STRAIN CODE 027; Charles River, St-Constant, 
QC, Canada). The genotypes were determined as described previously[40, 41]. The animals were kept 
on a 12h light/dark cycle with water and standard laboratory chow ad libitum (2018; Teklab Premier 
Laboratory Diets, Madison, WI). Female mice in these experiments were 8-10 weeks of age, and were 
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separated into 4 groups (Sedentary R
+
A
+
 and non-transgenic (R
-
A
-
); Trained R
+
A
+
 and  
R
-
A
-
). Their care met the standards set forth by the Canadian Council on Animal Care for the use of 
experimental animals. All procedures were approved by the Animal Care Committee of the CHUM 
Research Centre. 
 
ExT. Mice were placed in cages with free access to a running wheel, for one month before 
mating and remained in these cages throughout gestation as done previously in a different 
mouse model of PE where we have shown significant improvement in maternal outcomes this 
type of Ext regimen[16]. The use of voluntary exercise was chosen to prevent the stress that is 
usually associated with treadmill running[42]. ExT was measured, as each cage was connected 
to a computer and, the number of revolutions could be recorded and used to confirm training 
status (Compte-tour5, Aquila, Boucherville, Qc, Canada) as done previously[16].  
 
Arterial pressure measurement. Arterial pressure (AP) and heart rate (HR) were quantified in 
the carotid artery by telemetry using TA11PA-C10 probes (Data Sciences International, St. 
Paul, MN) as done previously[43, 44]. After 7-10 days of recovery post-surgery, AP and HR 
were recorded for 3 consecutive days to represent baseline values. The mice were then put in 
cages with access to an exercise wheel for 1 month. Sedentary animals were placed in standard 
cages. After this period, male mice were introduced into the cages for timed-mating of trained 
animals, while the reverse was performed for sedentary females.  Gestation was confirmed by 
the presence of a vaginal plug, which was recorded as day 1 of pregnancy. AP and HR 
measurements were recorded every 2 days, beginning on day 1 up to day 19, and then 
measurements were collected continuously until 48 h post-partum.  Since mice normally give 
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birth between day 19 and 21 of gestation, the day prior to delivery was considered as “end of 
gestation” to permit an adequate comparison. 
 
Proteinuria: Urine samples were collected on day 0 (prior to mating) and on day 18 (prior to 
sacrifice) and albumin and creatinine were assayed as done previously[16, 18].  
 
Echocardiography. Transthoracic echocardiographic studies were performed prior to mating 
and at the end of pregnancy by high-resolution ultrasound biomicroscopy (Vevo660; 
Visualsonics, Toronto, ON, Canada) equipped with a 25-55 MHz probe, as previously 
described[18].  
 
Tissue collection and histology. On day 18 of gestation, mice were anesthetized by isoflurane 
2-3% in oxygen, and then maintained on 2% isoflurane. Blood was collected by intrathoracic 
cardiac puncture and placed in a chilled 1.5 ml tube containing EDTA (EMD, Gibbstown, NJ, 
USA). Plasma was separated by centrifugation and samples were snap frozen in liquid 
nitrogen, and stored at -80
o
C until assayed. The pups were weighed, and their tails were cut 
and kept for genotyping. Heart and placentas were all collected, weighed, and either snap-
frozen in liquid nitrogen or fixed for future experiments as done previously[16, 18].  
 
Immunohistochemistry. Immunochemical analysis was assessed from 3 different placentas 
issued from 3 different mothers/group as done previously[16]. Paraffin-embedded placentas 
were sectioned at 4 μm and deparaffinised to assess cytokeratin (1:800; ab9377, Abcam, 
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Cambridge, MA) and Histone H3 (1:1600; ab5176-100, Abcam) to evaluate trophoblasts at all 
stages and mitosis, respectively[45, 46].  
 
Western Blot. Frozen placentas and aortas were lyophilized and subsequently homogenised in 
lysis buffer. Total protein content was measured in supernatants by standard Bradford assay. 
50µg of protein were loaded on 10% or 12% sodium dodecyl sulfate (SDS)-polyacrylamide 
gel, depending on the molecular weight of the protein studied, and separated by 
electrophoresis. Proteins were transferred on a nitrocellulose membrane (Amersham, Baie 
d’Urfe, QC). The following antibodies and concentrations were used: vascular endothelial 
growth factor (VEGF) (1:1000, ab46154, Abcam, Cambridge, MA); angiotensin converting 
enzyme 2 (ACE2) (1:500, SC-20998, Santa Cruz Biotechnology, Santa Cruz, CA); 
Angiotensin-(1-7)-Mas receptor (MasR) (1:2000, AAR-013, Alamone Labs, Jerusalem, 
Isreal); AT1R (1:2000, SC-578, Santa Cruz Biotechnology, Santa Cruz, CA); glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (1:2000, SC-20357, Santa Cruz Biotechnology, Santa 
Cruz, CA). Each protein signal was normalized to their respective GAPDH band. 
 
Real-time PCR. Total RNA was extracted from frozen samples using Trizol (Invitrogen, 
Burlington, ON, Canada) according to the manufacturer’s protocol. Removal of genomic 
DNA, reverse transcriptase reaction and real-time PCR were conducted as previously 
reported(18). In brief, real-time PCR was done using SYBR green chemistry and the following 
genes were investigated: 40S ribosomal protein S16 (S16), sFlt-1, NGFI-A-binding protein 1 
(Nab1) and brain natriuretic peptide (BNP). Primer sequences are described in Table S1 
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(please see online supplement). Each sample was run and analyzed in duplicate, and is 
expressed as relative to s16 mRNA. 
 
Plasma sFlt-1 levels: Circulating sFlt-1concentrations were measured using a commercial 
ELISA kit (R&D-Quantikine, Minneapolis, MN). Plasma samples were diluted 1:20 using the 
manufacturer’s dilutor prior to the experiment and each sample was measured in duplicate.  
 
Plasma glucose levels: Circulating glucose levels were determined using a commercially 
available enzymatic kit (Autokit Glucose, WAKO Diagnositics, Richmond, VA), following 
the manufacturer’s instructions. Each sample was measured in duplicate. 
 
Statistical analysis. All values are expressed as means ± SE. A p-value of ≤ 0.05 was 
considered significant. Differences in tissue weights and ratios, number of pups, circulating 
glucose and sFlt-1 levels, as well as data obtained by real-time PCR, Western blot and 
immunohistochemistry were computed by 2-way ANOVA. 2-way repeated measures ANOVA 
was used to analyze echocardiography parameters, blood pressure and albumin/creatinine 
ratio. These analyses were all followed by Tukey’s post-hoc test if an interaction was detected.  
Placental alterations were analyzed using a non-parametric Mann-Whitney Rank Sum Test.  
 
A more detailed methods section can be found in the online supplement. Also present in this 
supplemental section are the results regarding the effects of exercise training and genotype on 
distance travelled prior to and throughout gestation, placental cytokeratin and histone H3 
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immunostaining, circulating glucose levels, maternal characteristics and cardiac parameters 
calculated and measured following echocardiography.  
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Figure legends 
 
Figure 1. Effect of training and genotype on mean arterial pressure (MAP) and 
proteinuria.  
The MAP (A) increase observed in the sedentary R
+
A
+
 mice at the end of gestation (n=7) was 
prevented by ExT (n=7). R
+
A
+
 mice also presented with a significant increase in 
albumin/creatinine ratio (ACR), compared with their non-transgenic counterparts (n=13), 
which was further worsened with pregnancy (B). The ACR of trained transgenic mice (n=14) 
was significantly reduced compared to sedentary R
+
A
+ 
mice (n=11). Values are expressed as 
means ± SE. ‡ p<0.05 significantly different from sedentary animals. ║p ≤ 0.05 and # p ≤ 
0.001, statistically different from before pregnancy (Day 0); ** p < 0.001, statistically 
different from R-A- mice. MAP, mean arterial pressure; END, end of pregnancy.  
 
Figure 2. Left ventricular gene expression of Nab1 and BNP. 
Nab1 and BNP gene expression were significantly decreased with ExT in both R
-
A
-
 and R
+
A
+
 
mice compared to their sedentary counterparts. Nab1 expression however was also 
significantly greater among R
+
A
+
 mice, compared to non-transgenic mice. Values are 
expressed as means ± SE. ‡ p<0.05 and § p<0.005 statistically different from sedentary mice; 
* p<0.05 statistically different from R
-
A
-
. For Nab1, sedentary R
-
A
-
 and trained R
+
A
+
, n=10; 
trained R
-
A
-
, n=8; sedentary R
+
A
+
, n=14. For BNP, sedentary R, n=11; trained r-, n=9; 
sedentary R+, n=14; trained R+, n=10.  
 
Figure 3. Effect of ExT and SPE on angiogenic balance. 
Sedentary R
+
A
+
 mice presented with significant increase in placental VEGF protein (A) and 
sFlt-1 mRNA (B) compared to their non-transgenic littermates, which was significantly 
decreased with ExT. Comparably, a significant increase in circulating sFlt-1(C) was observed 
among sedentary R
+
A
+ 
mice, which was absent in trained transgenic mice. Placental VEGF: 
Sedentary R
-
A
-
, n=5; trained R
-
A
-
, n=6; sedentary R
+
A
+
, n=5; trained R
+
A
+
, n=6. Placental 
sFlt-1 mRNA: Sedentary R
-
A
-
, n=6; trained R
-
A
-
, n=8; sedentary R
+
A
+
, n=7; trained R
+
A
+
, 
n=6. Circulating sFlt-1: Sedentary R
-
A
-
, n=8; trained R
-
A
-
, n=9; sedentary R
+
A
+
, n=11; trained 
R
+
A
+
, n=9. Values are expressed as mean ± SE.* p<0.05, † p<0.01, ** p<0.001 significantly 
different than R
-
A
-
 mice; ‡ p<0.05, § p<0.001 significantly different from sedentary mice. 
 
Figure 4. Modulation of placental AT1R, MasR and ACE2 protein expression by a SPE 
and ExT.   
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A significant increase in placental AT1R (A) could be observed in sedentary R
+
A
+
 mice, along 
with a significant reduction in MasR (B) and ACE2 (C). Both MasR and AT1 were 
normalized with ExT and AT1R was even decreased in non-transgenic mice. Conversely, 
ACE2 was unaffected by ExT. Values are expressed as mean ± SE. ‡ p<0.05 and § p<0.005 
statistically different from sedentary mice; * p < 0.05 and † p < 0.01 statistically different fron 
R
-
A
-
. Placental AT1R: Sedentary R
-
A
-
, n=3; trained R
-
A
-
, n=6; sedentary R
+
A
+
, n=7; trained 
R
+
A
+
, n=5. Placental MasR: Sedentary R
-
A
-
, n=5; trained R
-
A
-
, n=6; sedentary R
+
A
+
, n=7; 
trained R
+
A
+
, n=5. Placental ACE2: Sedentary R
-
A
-
, n=6; trained R
-
A
-
, n=8; sedentary R
+
A
+
, 
n=6; trained R
+
A
+
, n=6.   
 
Figure 5. Effect of SPE-like phenotype and exercise on aortic AT1R, MasR and ACE2 
protein expression, respectively.   
Aortic AT1R (A) expression was significant increased, while MasR (B) and ACE2 (C) 
expression were significantly reduced among R
+
A
+
 mice. Conversely, MasR (B) was 
significantly increased with ExT. Values are expressed as mean ± SE. ‡ p<0.05 statistically 
different than sedentary mice; * p < 0.05 statistically different than R
-
A
-
. Aortic AT1R: 
Sedentary R
-
A
-
, n=6; trained R
-
A
-
, n=7; sedentary R
+
A
+
, n=6; trained R
+
A
+
, n=5. Aortic 
MasR: Sedentary R
-
A
-
, n=5; trained R
-
A
-
, n=7; sedentary R
+
A
+
, n=6; trained R
+
A
+
, n=8. 
Aortic ACE2: Sedentary R
-
A
-
, n=6; trained R
-
A
-
, n=5; sedentary R
+
A
+
, n=6; trained R
+
A
+
, 
n=7.   
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 Mother’s 
genotype 
N Heart/tibia 
ratio 
LV/tibia 
ratio 
RV/tibia 
ratio 
LA/tibia 
ratio 
RA/tibia ratio 
Sedentary R-/A- 5 7.13 ± 0.32 5.27 ± 0.29 1.21 ± 0.07 0.18 ± 0.01 0.17 ± 0.02 
R+/A+ 5 9.54 ± 0.23† 7.35 ± 0.28† 1.47 ± 0.04* 0.20 ± 0.02 0.19 ± 0.02‡ 
Trained R-/A- 7 7.73 ± 0.18 5.17 ± 0.34 1.47 ± 0.07‡ 0.18 ± 0.01 0.21 ± 0.01 
R+/A+ 6 9.86 ± 0.36† 7.18 ± 0.26† 1.41 ± 0.04  0.22 ± 0.03 0.24 ± 0.02‡ 
Table 31: Effect of ExT and SPE on ratio of the whole heart and its compartments to tibia length at the end of pregnancy. 
Transgenic mice were found to have a statistically larger hearts, left ventricles, right ventricles and right atria, when corrected to left 
tibia length in comparison with their non-transgenic littermates without any effect of ExT. Right ventricles were also increased 
among the trained non-transgenic animals. Values are expressed as mean ± SE. * p ≤ 0.05, † p ≤ 0.001, significantly different from 
R-/A- mice; ‡ p ≤ 0.05 significantly different than sedentary mice. N, number; LV, left ventricle; RV, right ventricle; LA, left 
atrium; RA, right atrium.  
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 Mother’s 
genotype 
N Necrosis Hyalinization Microcal. GCIL LLTS Total 
   Mdn 75% Mdn 75% Mdn 75% Mdn 75% Mdn 75% Mdn 75% 
Sedentar
y 
R
-
A 22 0.0 1.0 0.5 1.0 0.0 0.0 0.0 0.0 0.0 1.0 1.0 2.0 
R
+
A
+
 21 1.0 2.0 2.0* 2.0 0.0 0.0 1.0* 1.0 1.0* 2.0 4.0* 6.0 
Trained R
+
A
+
 25 1.0 1.0 0.0‡ 1.0 0.0 0.0 0.0 0.25 1.0‡ 1.0 2.0‡ 3.0 
 
Table 42: Characterization of placental pathology. 
Results are expressed as the median (Mdn) and the 75th percentile of the score given in histology. ‡ p≤0.05 significantly different 
from sedentary mice. * p≤0.05 significantly from non-transgenic mice. GCIL, Giant cell island loss; LLTS, Loss of labyrinthine 
trophoblast structure; Mdn, Median; Microcal., Microcalcification. 
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 Mother’s 
phenotype 
Total fetal 
weight (g) 
Total 
placental 
weight (g) 
Fetal/placental 
weight ratio 
Litter size 
Sedentary R
-
A
-
 6.41 ± 0.42 0.92 ± 0.08 7.14 ± 0.15 8.9 ± 0.6 
R
+
A
+
 5.23 ± 0.25* 0.73 ± 0.04* 7.38 ± 0.18 7.0 ± 0.4† 
Trained R
-
A
-
 6.41 ± 0.45  0.82 ± 0.05 7.96 ± 0.12§ 8.1 ± 0.6 
R
+
A
+
 7.07 ± 0.32§ 0.92 ± 0.05‡ 7.73 ± 0.16§ 9.6 ± 0.4§   
Table 53. Fetal consequences of SPE-like phenotype and ExT. 
Training was found to significantly increase total fetal and placenta weight, fetal/placental 
weight ratio and litter size in R
+
A
+
 mice compared to their sedentary littermates. Conversely, 
sedentary transgenic mice has a significant decrease in all of these parameters. Fetal/placental 
weigth ration was also found to be increased with ExT in the non-transgenic mice. 8 litters 
were used for each of the groups studied. Values are expressed as mean ± SE. ‡ p<0.05 and § 
p<0.005 statistically different from sedentary mice; * p<0.05 and † p<0.01 statistically 
different from R-A- mice.  
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Figure 31. Effect of training and genotype on mean arterial pressure (MAP) and 
proteinuria. 
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Figure 42. Left ventricular gene expression of Nab1 and BNP. 
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Figure 53. Effect of ExT and SPE on angiogenic balance.  
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Figure 64. Modulation of placental AT1R, MasR and ACE2 protein expression by a SPE 
and ExT.  
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Figure 75. Effect of SPE-like phenotype and exercise on aortic AT1R, MasR and ACE2 
protein expression, respectively.  
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SUPPLEMENTAL MATERIAL 
 
Detailed Methods 
 
Animals. R
+
A
+
 transgenic mice were produced by breeding heterozygous human renin mice 
(Ren9 line)[1] with heterozygous human angiotensinogen mice (204/1 line)[2]. Both single 
transgenic lines were originally obtained from Dr. Curt D. Sigmund of the University of Iowa, 
and were maintained in our animal facility by backcrossing with C57BL/6 mice (strain code 
027, Charles River, St-Constant, QC, Canada) for over 20 generations. The genotypes were 
determined by performing a polymerase chain reaction on genomic DNA obtained from tail 
biopsies using primers specific to hREN and hANG (see Table S1 for sequence). Each 
reaction contained 1μl 10X buffer; 0.2 μl 10mM dNTP, 0.1 μl of each primer, 6.4 μl  of water, 
0.5 μl taq polymerase (Feldan, Québec, QC, Canada) and 2 μl of genomic DNA. The PCR 
products were subsequently analyzed by southern blot using a 1% agarose gel. The animals 
were kept on a 12h light/dark cycle with water and standard laboratory chow (2018; Teklab 
Premier Laboratory Diets, Madison, WI) ad libitum. Female mice in these experiments were 
8-10 weeks of age, and were separated into 4 groups (Sedentary R
+
A
+
 and non-transgenic (R
-
A
-
); Trained R
+
A
+
 and R
-
A
-
). R
+
A
+
 mice were bred with non-transgenic (NT) males. Control 
mice corresponded to NT littermates. The care of all mice met the standards set forth by the 
Canadian Council on Animal Care for the use of experimental animals. All procedures were 
approved by the Animal Care Committee of the CHUM Research Centre.  
 
Exercise training. Mice were placed in cages with free access to a running wheel, for one 
month and remained in these cages throughout gestation. In fact, studies have shown 
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significant improvements in aerobic capacity with only 3 weeks of exercise training (ExT) 
with a running wheel[3, 4]. In addition, we have shown significant improvement in maternal 
outcomes in a different mouse model with this type of Ext regimen[5]. The use of voluntary 
exercise was chosen to prevent the stress that is usually associated with treadmill running[6]. 
ExT was measured, as each cage was connected to a computer and, the number of revolutions 
were recorded and used to confirm training status (Compte-tour5, Aquila, Boucherville, Qc, 
Canada).  
 
Arterial pressure measurement. Arterial pressure (AP) and heart rate (HR) were quantified in 
the carotid artery by telemetry using TA11PA-C10 probes (Data Sciences International, St. 
Paul, MN) [7, 8]. The probe’s catheter was inserted into the left carotid artery of female mice 
anesthetized by inhalation of isoflurane 2-3% in oxygen, and maintained on 2% isoflurane. 
After 7-10 days of recovery post-surgery, AP and HR were recorded for 3 consecutive days to 
represent baseline values. The mice were then put in cages with access to an exercise wheel 
for 1 month. Sedentary animals were placed in standard cages. After this period, male mice 
were introduced into the cages for timed-mating of trained animals, while the reverse was 
performed for sedentary females.  Gestation was confirmed by the presence of a vaginal plug, 
which was recorded as day 1 of pregnancy. AP and HR measurements were recorded every 2 
days, beginning on day 1 up to day 19.  Since mice normally give birth between day 19 and 21 
of gestation, the day prior to delivery was considered as “end of gestation” to permit an 
adequate comparison. 
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Proteinuria. Urine samples were collected on day 0 (prior to mating) and on day 18 (prior to 
sacrifice). In order to do so, the mice were momentarily restrained and their urine was directly 
collected in a 1.5mL tube. Collecting urine via this method is associated with minimal amount 
of stress, which is far less than that associated with placing mice in metabolic cages for 
24h[9]. Once collected, the urine samples were maintained at -80
o
C until assayed. Albuwell 
and Creatinine companion ELISA kits were used to determine urine albumin and creatinine 
clearance, respectively (Exocell, Philadelphia, PA, United States). Urine samples were diluted 
1:10, and each sample was done in duplicate. Proteinuria was assessed by calculating the 
albumin/creatinine ratio (ACR).  
 
Echocardiography. Transthoracic echocardiographic studies were performed prior to training 
and mating, and at the end of pregnancy. The mice were anesthetized by inhalation of 
isoflurane 2-3% in oxygen, and maintained on 2% isoflurane and ultrasound transmission gel 
(Ecogel 200, EcoMed Inc., Mississauga, ON) was placed over the cardiothoracic region to 
provide an acoustic coupling medium between the probe and the animal. Their heart were 
investigated by high-resolution ultrasound biomicroscopy (Vevo660; Visualsonics, Toronto, 
ON, Canada) equipped with a 25-55 MHz probe. Positioning of the M-lines was guided by B-
mode echocardiography. The parasternal long-axis view served to capture M-mode tracings 
through the anterior and posterior left ventricular (LV) walls at the level of the papillary 
muscle. The ejection fraction (EF) was estimated by the following formula: EF = (LVEDV – 
LVESV)  100 / LVEDV, where LVEDV and LVESV are respectively LV end-diastolic and 
end-systolic volumes. LV fractional shortening (FS) was given by (LVEDD – LVESD)  100 
/ LVEDD. Lastly, LV volumes during diastole and systole were determined as 7  LVD3 / (2.4 
102 
 
+ LVD), where left ventricular diameter (LVD) is substituted by LVEDD for LV diastolic 
volume or LVESD for LV systolic volume, respectively. 
 
Tissue collection and histology. On day 18 of gestation, mice were anesthetized by isoflurane 
2-3% in oxygen, and then maintained on 2% isoflurane. Blood was collected by intrathoracic 
cardiac puncture and placed in a chilled 1.5 ml tube containing 15ul of 500mM EDTA (pH: 
8.0)  (EMD, Gibbstown, NJ, USA). Plasma was separated by centrifugation and samples were 
snap frozen in liquid nitrogen, and stored at -80
o
C until assayed. The pups were weighed, and 
their tails were cut and kept for genotyping. Kidneys, heart, and placentas were all collected, 
weighed, and either snap-frozen in liquid nitrogen or placed overnight in 4% 
paraformaldehyde for fixation. 24h after the tissues had been fixed, they were washed with 
phosphate buffer and subsequently embedded in paraffin. Sections were obtained by cross-
sectionally cutting the fixed tissue using a microtome. To evaluate placental morphology, the 
sections were stained with hematoxylin phloxine saffron (HPS) and evaluated by light 
microscopy. Embedding, sectioning and staining were performed by the histology platform of 
the Research Institute in Immunology and Cancerology at the Université de Montréal. 
Placental alterations were characterized by 5 criteria: necrosis, hyalinization, 
microcalcification, giant cell island loss and labyrinthine trophoblast structure loss. The latter 
two are analogous to human extravillous cytotrophoblasts cells and chorionic villi structure, 
respectively[10]. A score from 0 to 3 was assigned for each criterion: 0 for no change, 1 for 
mild, 2 for moderate, and 3 for severe alteration. All scores were then summed up for total 
evaluation of the placental alterations. To avoid any bias, the investigator scoring the tissues 
was blinded to the genotype of both mother and pups. 
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Real-time PCR. Total RNA was extracted from frozen samples using Trizol (Invitrogen, 
Burlington, ON, Canada) according to the manufacturer’s protocol. To remove genomic DNA, 
RNA samples were incubated with 2 U deoxyribonuclease I (DNase I; Invitrogen)/ug RNA for 
30 min at 37°C. Single-stranded cDNA was synthesized by reverse-transcriptase reaction with 
Moloney Murine Leukemia Virus (M-MLV) (Invitrogen). PCR was undertaken in the iCycler 
IQ Real Time PCR detection System (Bio-Rad Laboratories, Hercules, CA), using SYBR® 
green chemistry[11]. In brief, 2 µl of diluted cDNA was added to an 18 µl reaction mixture 
containing 1X iQ SYBR Green Supermix (Bio-Rad Laboratories) and 200 nM forward and 
reverse primers (Invitrogen). The following genes were investigated: 40S ribosomal protein 
S16 (S16), sFlt-1, NGFI-A-binding protein 1 (Nab1) and brain natriuretic peptide (BNP). 
Primer sequences are described in Table 1. Each placental and aortic sample was run and 
analyzed in duplicate. mRNA levels are expressed as values relative to s16 mRNA.  
 
Immunohistochemistry. Immunochemical analysis was assessed on 3 different placentas from 
3 different litters. Paraffin-embedded tissues were sectioned at 4 μm and deparaffinised in 
citrisolv (Fisher Scientific, Ottawa, ON, Canada). Antigen retrieval was performed by boiling 
the sections in sodium citrate buffer (10 nM, pH 6.0) for 3min. Immunostaining was then 
carried out with Catalyzed Signal Amplification System (Dako, Carpinteria, CA), according to 
the manufacturer’s instructions. The following modification were used: Peroxidase activity 
was blocked for 15min at room temperature with peroxidase block solution. Samples were 
rinsed in 3 baths for 3min in TBS-T (0.05 M tris-HCL, 0.3 M NaCl, 0.1% tween 20, pH 7.6). 
The sections were then incubated with endogenous avidin and biotin blocking solutions 
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(Thermo Scientific, Ottawa, ON, Canada) for 15min at room temperature. Non-specific 
antigen binding was blocked by incubation in protein block solution for 30min at room 
temperature. The sections were incubated overnight at 4ºC with specific immunohistochemical 
primary antibodies diluted in TBS with 1% bovine serum albumin at the following 
concentrations: anti-pan-cytokeratin (1:800; ab9377, Abcam, Cambridge, MA) and histone H3 
(1:1600; ab5176-100, Abcam)to evaluate the presence of trophoblast and mitosis, 
respectively[12, 13]. Tissue sections were incubated with secondary antibody conjugated to 
biotin (1:5000, donkey anti-rabbit; AP182B, Chemicon international, Millipore, Billerica, 
MA) solution for 1h at room temperature. Primary antibodies were omitted in the negative 
control. Samples were incubated with streptavidin-biotin complex for 15min and 
subsequently, with amplification reagent for 15min at room temperature. The sections were 
then incubated with a streptavidin-peroxidase for 15 min. Lastly, staining with substrate-
chromogen solution for 4min and counterstaining with Mayer’s hematoxylin (Sigma-Aldrich, 
Oakville, ON, Canada) blue in 0.3% ammonia water were performed. Sections were viewed 
and photographed with a Leitz Diaplan microscope equipped with a Nikon CoolPix 990 
camera (Nikon Instruments, Melville, NY). 
 
Western Blot. Frozen placentas and aortas were lyophilized and subsequently homogenised in 
lysis buffer (50mM HEPES pH 7.5, 137mM NaCl, 1mM MgCl2, 1mM CaCl2, 2mM Na3VO4, 
10mM Na pyrophosphate, 10mM NaF, 2mM EDTA, 1% NP-40, 10% glycerol, 34mg/L PMSF 
along with a protease inhibitor cocktail (Roche, Mississauga, ON, Canada)). Total protein 
content was measured in supernatants by standard Bradford assay. Samples containing 50µg 
of protein were loaded on 10% or 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel, 
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depending on the molecular weight of the protein studied, and separated by electrophoresis. 
Proteins were transferred on a nitrocellulose membrane (Amersham, Baie d’Urfe, QC). 
Placental and aortic non-specific sites were blocked overnight at 4
o
C in SuperBlock buffer 
(Thermo Fisher Scientific, Rockford, IL) or in Bløk
TM
-Chemiluminescent blocker (Millipore, 
Temecula, MA), respectively. Membranes were then incubated with the primary antibody in 
10% Superblock and 0.1% Tween 20 (Fisher Scientific, Ottawa, ON, Canada) in tris buffered 
solution (TBS) (Abcam, Cambridge, MA) overnight at 4˚C. The following antibodies and 
concentrations were used: vascular endothelial growth factor (VEGF) (1:1000, ab46154, 
Abcam, Cambridge, MA); angiotensin converting enzyme 2 (ACE2) (1:500, SC-20998, Santa 
Cruz Biotechnology, Santa Cruz, CA); Angiotensin-(1-7)-Mas receptor (MasR) (1:2000, 
AAR-013, Alamone Labs, Jerusalem, Israel); AT1R (1:2000, SC-578, Santa Cruz 
Biotechnology, Santa Cruz, CA); glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(1:2000, SC-20357, Santa Cruz Biotechnology, Santa Cruz, CA). The membranes were 
subsequently washed with 0.1% TBS-T for 30min and incubated for 1h at room temperature 
with their respective horseradish peroxidase conjugated secondary antibody (1:3000, 1:10 
Superblock in 0.1% Tween 20  in TBS) independent of primary antibody used. The GAPDH 
antibody was already linked to horseradish peroxidise, and thus, a secondary antibody was not 
use for this experiment. Bands were revealed using the ECL West Pico kit (Pierce, Rockford, 
IL). Each protein signal was normalized to its respective GAPDH band. 
 
Plasma sFlt-1 levels: Circulating sFlt-1concentrations were measured using a commercial 
ELISA kit (R&D-Quantikine, Minneapolis, MN). Plasma samples were diluted 1:20 using the 
manufacturer’s dilutor prior to the experiment and each sample was measured in duplicate.  
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Plasma glucose levels: Circulating glucose levels were determined using a commercially 
available enzymatic kit (Autokit Glucose, WAKO Diagnositics, Richmond, VA), following 
the manufacturer’s instructions. Each sample was measured in duplicate. 
 
Statistical analysis. All values are expressed as means ± SE. A p-value of ≤ 0.05 was 
considered significant. Differences in tissue weights and ratios, number of pups, circulating 
glucose and sFlt-1 levels, as well as data obtained by real-time PCR, Western blot and 
immunohistochemistry were computed by 2-way ANOVA. 2-way repeated measures ANOVA 
was used to analyze echocardiography parameters, blood pressure and albumin/creatinine 
ratio. These analyses were all followed by Tukey’s post-hoc test if an interaction was detected.  
Placental alterations were analyzed using a non-parametric Mann-Whitney Rank Sum Test.  
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Supplemental Figures 
 
 
 
Figure 8S1: Distance travelled prior to and throughout gestation. 
Exercise training patterns were similar regardless of genotype (R
-
A
-
 (n=10) and R
+
A
+
 (n=11)). 
Training was greater prior to pregnancy in both groups, and decreased progressively as 
pregnancy advanced, reaching a nadir prior to sacrifice.  W, average distance travelled weekly; 
N, distance travelled during nighttime; END, end of pregnancy.  
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Figure 9S2: Effects of exercise training and SPE on placental cytokeratin 
immunostaining. 
Cytokeratin is a marker of trophoblast proliferation at all stages of gestation. Histological 
analysis revealed a significant increase in cytokeratin positive trophoblastic cells among 
sedentary transgenic mice (Image C, n=3), compared to their nontransgenic counterparts 
(Image A, n=3). Interestingly, training led to a significant reduction in trophoblast positive 
staining among R
+
A
+
 mice (Image D, n=3). A small increase in cytokeratin was observed 
among trained R
-
A
-
 (Image B, n=3), compared to their sedentary counterparts (Image A, n=3). 
These results suggest that both phenotype and training may affect trophoblast function, and, 
consequently, fetal development. Additionally, these results are in line with studies 
demonstrating an increase in placental villous area and perfusion with exercise training. 
Magnification 200 X. 
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Figure 10S3: Effects of exercise training and SPE on placental histone H3 
immunostaining. 
Histone H3-phospho-immunostaining is a marker of mitosis, which allows distinguishing 
proliferating from endoreplicating cells (a phenomenon specific to trophoblastic giant cell). A 
weak increase in histone H3 staining was observed with training among the R
-
A
-
 mice (Image 
B, n=3), compared to sedentary R
-
A
-
 mothers (Image A, n=3). Sedentary transgenic dams has 
significantly more histone H3 immunostaining (Image C, n=3), which disappeared with 
training. In sedentary R
+
A
+
 mice, the staining was primarily localized in peripheral 
trophoblasts, demonstrating an increase in number of cells undergoing endoreplication. 
Magnification 200 X.    
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Figure 11S4: Changes in circulating glucose levels with ExT and SPE-like phenotype. 
Circulating glucose levels were consistently lower among trained animals compared with their 
sedentary counterparts, irrespective of genotype (n=10, per group). Values are expressed as 
means ± SE.  * p<0.05 sig 
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Supplemental Tables: 
 
Primer Forward Reverse 
s16 5’-ATCTCAAAGGCCCTGGTCGC-3’ 5’-ACAAAGGTAAACCCCGATCC-3’ 
sFlt-1 5’- AGGTGAGCACTGCGGCA-3’ 5’-ATGAGTCCTTTAATGTTTGA-3’ 
Nab1 5’-CTGGCCAGGGTTTCTC-3’ 5’-TGGCACAGATTCCTGGAAGTC-3’ 
BNP 5’-AATTCCAAGGTGACACATATC TC-3’ 5’-GGTCTTCCTACAACAACTTCAG-3’ 
hREN 5’-TGACACTGGTTCGTCCAATG-3’ 5’-ATA GCG GAG GGT GAG TTC TG-3’ 
hANG 5’-TGGTGCTAGTCGCTGCAAAACTTGACACCG-3’ 5’-CAGGGAGCAGCCAGTCTTCCATCCTGTCAC-3’ 
Table 6S1: Primer sequences used for real-time PCR. 
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Mother’s 
genotype 
N Baseline weight  
(grams) 
Weight gain  
(grams) 
Length of pregnancy  
(days) 
Sedentary     
R
-
A
- 
11 21.67 ± 0.23 13.9 ± 0.68 19.0 ± 0.0 
R
+
A
+
 10 22.54 ± 0.42 13.95 ± 0.84 19.1 ± 0.01 
Trained     
R
-
A
-
 10 21.14 ± 0.59 12.61 ± 0.80 19.0 ± 0.0 
R
+
A
+
 11 21.32 ± 0.43 14.44 ± 0.52 19.2 ± 0.2 
Table 7S2: Maternal characteristics. 
No statistical significance could be detected on baseline body weight, weight gain and length of pregnancy. Values are expressed as 
mean ± SE. N, number; BW, body weight; LV, left ventricle; LK, left kidney.  
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 Mother’s 
genotype 
N LV diastolic 
volume  (μl) 
LV systolic  
volume (μl) 
FS (%) EF (%) 
Before Pregnancy       
Sedentary R-/A- 8 62.31±4.52 29.38±1.56 26.46±1.00 52.28±1.52 
R+/A+ 8 59.66±3.03  30.96±3.01 23.02±1.46* 46.59±2.40* 
Trained R-/A- 9 61.87±3.83 29.27±2.12 26.14±0.70 51.83±1.12 
R+/A+ 12 66.98±3.68 34.80±3.60 24.98±2.13* 48.67±3.27* 
End of Pregnancy       
Sedentary R-/A- 8 67.71±4.07║ 31.85±4.36 28.01±2.47 54.16±3.91 
R+/A+ 8 70.54±2.32║ 34.61±2.82 25.93±1.97* 50.99±3.13* 
Trained R-/A- 9 73.81±5.17║ 35.73±2.88 28.81±1.74 55.32±2.63 
R+/A+ 12 74.38±4.72║ 35.92±3.83 26.98±1.84* 51.93±2.72* 
Table 8S3: Cardiac parameters calculated following echocardiography. 
Left ventricular diastolic volume was increased at the end of pregnancy in all groups among the sedentary R
+
A
+
 both before and at 
the end of pregnancy. There was a non-significant decrease in fractional shortening and ejection fraction, accompanied by an 
increase. Similarly, a non-significant increase in left ventricular systolic volume was observed among sedentary transgenic dams, in 
comparison with their sedentary and nontransgenic counterparts. Values are expressed as means ± SE.║ p≤0.05, statistically 
different from the non-pregnant state, and * p≤0.05, statistically different from the R-A- genotype. N, number; LV, left ventricular; 
FS, Fractional shortening; EF, Ejection fraction.  
114 
 
 
 Mother’s 
genotype 
N Systolic 
LVID (mm) 
Diastolic LVID 
(mm) 
Systolic 
LVPW (mm) 
Diastolic 
LVPW (mm) 
Systolic  
IVS(mm) 
Diastolic 
IVS(mm) 
Before Pregnancy         
Sedentary R-/A- 8 2.78 ± 0.06 3.79 ± 0.11 1.60 ± 0.10 1.45 ± 0.15 1.18 ± 0.03 0.82 ± 0.02 
R+/A+ 8 2.82 ± 0.12 3.72 ± 0.08 1.84 ± 0.08 1.69 ± 0.08 1.35 ± 0.08 1.00 ± 0.05* 
Trained R-/A- 9 2.77 ± 0.09 3.78 ± 0.10 1.85 ± 0.15 1.78 ± 0.16 1.18 ± 0.05 0.88 ± 0.07 
R+/A+ 12 2.94 ± 0.13 3.91 ± 0.09 1.88 ± 0.06 1.69 ± 0.07 1.35 ± 0.09 1.02 ± 0.06* 
End of Pregnancy         
Sedentary R-/A- 8 2.84 ± 0.16 3.93 ± 0.10║ 1.95 ± 0.19 1.79 ± 0.16 1.36 ±0.09║ 0.95 ± 0.07║ 
R+/A+ 8 2.97 ± 0.10 4.01 ± 0.06║ 2.02 ± 0.13 1.89 ± 0.19 1.46 ± 0.09║ 1.05 ± 0.05║* 
Trained R-/A- 9 2.88 ± 0.13 4.04 ± 0.16║ 1.64 ± 0.14 1.57 ± 0.16 1.44 ± 0.08║ 1.08 ± 0.14║ 
R+/A+ 12 2.99 ± 0.15 4.08 ± 0.12║ 1.91 ± 0.16 1.77 ± 0.17 1.39 ± 0.08║ 1.07 ± 0.06║* 
Table 9S4: Cardiac parameters calculated following echocardiography. 
A significant increase in diastolic LVID was observed at the end of pregnancy, independent of genotype and training. Additionally, 
systolic IVS was significantly increased at the end of pregnancy among nontransgenic animals. The above values are expressed as 
mean ± SE. ║ p≤0.05, statistically different from the non-pregnant state, and * p≤0.05, statistically different from the R-A- 
genotype. N, number; LVID, left ventricular internal diameter; LVPW, left ventricular posterior wall thickness; IVS, 
interventricular septum.  
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Chapter 7: Discussion 
 
This animal study is the first of its kind to demonstrate the protective effect of 
exercise training on an SPE model in addition to elucidating potential mechanisms 
implicated in these effects. The R
+
A
+ 
animal model used in this study has recently 
been characterized in our laboratory[294]. As previously shown, the R
+
A
+
 
pregnant mice developed a further increase in AP, proteinuria, placental alterations 
and cardiac hypertrophy while the pups developed IUGR[294]. Although clinical 
features have been characterized, it is essential to identify mechanisms implicated 
in disease development since the etiology appears to be complex and 
multifactorial, and little is known about this specific type of PE (i.e. SPE).  
 
Although the amount of exercise performed by our trained mice may seem 
impressive, the cardiovascular benefits are comparable to those observed in 
humans who train 45 minutes, 3-4 times weekly[295-297]. Moreover, much like 
what women do instinctively, our trained mice significantly reduced their exercise 
volume upon conceiving, and continued to do so progressively during pregnancy, 
reaching a minimum around day 18, at which point the animals were sacrificed. As 
such, we feel that this form of exercise training is ideal for this type of study as it 
best represents what would be observed in pregnant women. Moreover, in our 
study, this type of moderate and voluntary exercise training before and during 
pregnancy attenuated a number of PE-like features, including the increase in AP 
seen at term.  
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Interestingly, we have identified the Ang-(1-7) axis as a likely player implicated in 
AP regulation during pregnancy. Indeed, we observed a significant increase in 
aortic MasR and a non-significant trend for an elevation in aortic ACE2 with 
exercise training, suggesting an enhanced Ang-(1-7) axis. Moreover, it may 
potentially produce a reduction in AngII signalling as ACE2 promotes the 
conversion of AngII into Ang-(1-7), thereby further promoting the beneficial 
effects of Ang-(1-7) and diminishing the deleterious effects mediated by AngII. 
Taken together, the overall effect would be an increased vasodilation through the 
stimulation of the MasR and a reduced effect of the AT1R. Other mechanisms 
aimed at promoting endothelial function are likely involved in preventing this rise 
in AP, including an enhanced production of NO with exercise training[231]. Along 
the same line, an increase in NO may explain the reduction in proteinuria observed 
in trained R
+
A
+
, compared to their sedentary counterparts.  
 
The kidney is also equipped with a local renin-angiotensin system. Hence, given 
the results obtained in the aorta regarding the RAS as well as the lack of increase 
in proteinuria with exercise training in our animal model, an investigation of the 
renal RAS components, including ACE, ACE2, AT1R and MasR, would be 
interesting to conduct in R
+
A
+
 mice, since modulation of this local system has 
been implicated in causing renal disease[25]. Moreover, a downregulation in renal 
AT1R has also been observed among SHR that experience a decrease in AP in 
response to chronic exercise training[298]. It is thus possible that a local 
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modulation of the renal RAS may be involved in the development of the disease as 
well as in the prevention of PE-like features by exercise training. 
 
Abnormal placentation is proposed to be the initiating factor in many PE cases. 
Our sedentary transgenic mothers have a significant increase in placental 
alterations, yet these are completely normalized with exercise training. 
Immunostaining against histone H3 and cytokeratin, which are markers of mitosis 
and trophoblast proliferation respectively, were also normalized with exercise 
training, as was placental expression of VEGF. Hypoxia is known to induce cell 
proliferation and inhibit cell differentiation, in addition to stimulating the 
production of VEGF[10, 11, 299]. Therefore, these results suggest that exercise 
prevents hyperproliferation of placental cytotrophoblasts and consequently, 
placental hypoxia.  
 
This placental hypoxia is likely responsible for the hindered fetal growth and 
development present in our animal model. Indeed, we observed a reduction in total 
fetal and total placental weight in sedentary R
+
A
+
 mice which was completely 
normalized by exercise training. This suggests that the placentas from the R
+
A
+
 
sedentary females are less effective at nourishing the fetus, but that this was 
normalized by exercise training. In addition, exercise training was found to 
significantly increase fetal/placental weight ratio in both transgenic and non-
transgenic mice further suggesting that it improves the placenta’s capacity to 
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supply the fetus with oxygen and nutrients. This is thus comparable to what is 
observed in normal human pregnancy, where exercise training is known to 
improve placental functional volume[264]. Moreover, this explains why total fetal 
weight is increased with exercise training. As such, exercise training may not only 
be effective at preventing IUGR in PE but it may also improve fetal growth in 
association with other diseases. Interestingly, sedentary R
+
A
+
 mice have 
significantly smaller litter size, which is normalized with exercise training. The 
benefits of exercise training may thus extend beyond cardiovascular and 
hemodynamics adaptations, to modulating the implantation process. Therefore, it 
may be very interesting to explore the impact of exercise training on fertility, as 
these seem to be more prevalent in our society particularly given the increasing 
maternal age at fertilization[50, 52] . 
  
Another mechanism that was identified was the modulation of the uteroplacental 
RAS components by the R+A+ genotype and exercise training. Indeed, we found 
that placental AT1R were significantly increased in our sedentary transgenic 
model and significantly reduced with exercise training. As such, this may be 
implicated in the modulation of blood flow to the fetus. Moreover, activation of 
the AT1R by AngII has also been found to inhibit trophoblastic invasion in vitro 
via the action of the plasminogen activating inhibitor (PAI)-1[300]. A PE-
associated increase in PAI-1 is also implicated in preventing fibrinolysis, thereby 
contributing to the development of microvascular thrombi[301]. This provides 
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further support to the deleterious effects of RAS overstimulation during 
pregnancy. Interestingly, placental MasR was significantly reduced in our 
sedentary R
+
A
+
 mice, suggesting that reduced Ang-(1-7) vasodilation may be 
involved in further compromising fetal delivery of nutrients and gases. 
Conversely, this was normalized with exercise training, which contributed to the 
normalisation of total fetal weight. Upregulation of the Ang-(1-7) axis thus 
appears to positively impact placental development and subsequently fetal 
development. It would be of interest to study the impact of Ang (1-7) 
administration on PE-like features in this model to see if it can also prevent the 
disease, thereby providing a novel potential therapeutic avenue. 
 
In addition, we found that exercise training significantly reduced placental sFlt-1 
mRNA and circulating sFlt-1, a protein capable of antagonizing circulating levels 
of VEGF and PlGF, suggesting that angiogenic balance is improved. Indeed, PE is 
often associated with increased levels of sFlt-1, in addition to sEng. This increase 
in anti-angiogenic factors has been suggested to contribute to the development of 
widespread endothelial dysfunction by antagonizing VEGF and TGF-1[217]. 
Indeed, evidence has shown that injection of sFlt-1 and sEng into pregnant rats 
causes hypertension, proteinuria and the HELLP syndrome, and reduces fetal 
weight[144]. In non-pregnant rats, hypertension and proteinuria are also observed. 
Moreover, given that AngII has been shown to promote the placental production 
and secretion of sFlt-1 through the stimulation of the AT1R, this further reinforces 
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our data suggesting that exercise training reduces PE-like features by decreasing 
the placental AngII axis in favour of the Ang-(1-7) axis[78, 145].  
We did not however investigate the effects of exercise training on sEng, nor its 
ligand (TGF3), which have also been involved in the development of PE. 
Consequently, it would be of value to test if exercise training also modulates these 
components, as well as if they are implicated in the development of PE-like 
features in our animal model, similar to what is observed in the human condition.  
 
Future research should also explore the presence of AT1-AA should be explored in 
the R
+
A
+
 model, as they have been found in the hANG rat model of PE[302]. The 
hANG rat corresponds to a model of de novo PE, in which a female rat 
overexpressing hANG is crossed with a male overexpressing hREN. Because of 
the species specificity of the RAS, the PE-like features develop upon mating and 
give rise to de novo hypertension and proteinuria, in addition to placental 
alterations and pathological cardiac hypertrophy. The identification of AT1-AA in 
this animal model, in addition to its presence in the sera of some PE patients, has 
suggested to be yet another mechanism implicated in the pathogenesis of the 
disease[302, 303]. How these antibodies develop is not completely understood, but 
infusion of IL-17 into pregnant rats has been shown to cause a significant increase 
in AT1-AA, via the intermediary of oxidative damage[304]. In the circulation, the 
AT1-AA have strong affinity for the AT1 receptor, and as such can activate the 
downstream signalling pathways of this receptor, producing vasoconstriction, 
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oxidative stress, hypertrophy, proliferation, and inhibiting fibrinolysis[65, 180]. 
Determining how these AT1-AA develop requires further investigation and 
necessitates the use of animal models of PE. Investigating whether exercise 
training can alter circulating levels of AT1-AA will provide a more complete 
understanding of the impact of exercise training in PE prevention.  
 
Cardiac hypertrophy was evident in our sedentary R
+
A
+
 mice, and this was 
associated with a significant increase in Nab1, which is a marker of pathological 
cardiac hypertrophy[305]. Interestingly, a significant reduction in Nab1 was 
observed with exercise training, although these values were not completely 
normalised. Moreover, BNP, a marker of LV dysfunction, was unaffected by 
pregnancy in our transgenic animal model, but was found to be decreased with 
exercise training[306]. Echocardiographic analysis were in accordance with these 
results as we observed a significant reduction in the EF and FS of sedentary R
+
A
+
 
mice at the end of gestation, compared to their non-transgenic counterparts which 
indicates that these animals had a decrease in cardiac function. Both parameters 
tended to be normalised with exercise training however this did not reach 
statistical significance. This is not that surprising since these mice remained 
hypertensive even with the exercise training and as such, the increased afterload 
surely contributes to the development of this pathological cardiac hypertrophy.  
Conversely, RAS overstimulation from birth may have caused the development of 
compensatory mechanisms to minimize cardiac injury[307]. It would thus be 
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interesting to evaluate the expression of local RAS components to determine their 
potential implication. Increases in ACE and AT1R, leading to activation of AngII-
mediated pathways, and decreases in MasR and ACE2, leading to depression of 
those mediated by Ang-(1-7), in sedentary R
+
A
+
 mice may explain why heart 
function is further compromised. Normalisation in these parameters may be 
implicated in the absence of worsening effects on cardiac hypertrophy and the 
observed trend towards an improvement in FS and EF with exercise training in the 
transgenic animal model.  
 
It is important to note that pregnancy in mice does differ in some points from that 
of the human gestation in that human trophoblastic invasion is deep while murine 
invasion is generally more superficial[308]. PE is characterized by inadequate, and 
thus superficial, trophoblastic invasion[309]. This difference in the placentation 
may limit the conclusions that can be made from mice models of PE. Nevertheless, 
it is important to mention that there are important similarities between murine and 
human pregnancy. In fact, both species necessitate a hemochorial placentation and 
require similar cardiovascular adaptations for pregnancy to ensue[2, 310]. 
Additionally, features that develop during gestation in our mouse model do 
resemble those that are observed in women who suffer from SPE[294]. Indeed, 
these mice develop a further increase in AP, proteinuria, cardiac hypertrophy and 
placental abnormalities, and their fetuses suffer from IUGR. Hence, we feel this 
animal model will be very useful to understand the mechanism involved in the 
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pathogenesis of these features and will provide a great deal of insight into the 
causes of SPE. Indeed, the use of animal models permits us to investigate the 
singular effect of exercise training on PE risk, as it is possible to hold most 
parameters constant, including environment and genetic background, and is thus 
an asset for any research. Moreover, invasive and timeline studies are also possible 
and can contribute to the investigation of potential therapeutic agents. 
 
The diverse beneficial effects of exercise training in healthy individuals are well 
known[82, 224, 225]. Identifying whether all the mechanisms implicated in these 
effects are also involved in protecting against PE will need to be investigated. 
Moreover, the determination of the factors which are implicated in the beneficial 
effects of exercise training may give us some new insights into the 
pathophysiology of the disease as well as suggest potential novel therapeutics. 
Currently, inflammation, immune response, oxidative stress and endothelial 
dysfunction are postulated PE etiologies[62]. As such, it would be interesting to 
investigate the effects of exercise training during normal and preeclamptic 
pregnancies on these systems in several tissues, including the vasculature, the 
placenta, the heart and the kidneys. Moreover, temporal analysis of associate 
markers during pregnancy will likely shed light on the progression of PE-like 
features and may suggest critical time points for the administration of novel 
treatments. For instance, iNOS expression is augmented in placentas of 
preeclamptic women and may be implicated in the production of oxidative stress, 
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via peroxynitrite formation[39, 212]. It would thus be interesting to investigate 
whether an increase in iNOS, normally expressed under pathological conditions, 
and/or a decrease in eNOS, expressed under physiological conditions, are observed 
in our sedentary transgenic mothers in the vasculature, the heart, the placenta and 
the kidney[312, 313]. This may contribute to the development of the numerous 
symptoms associated with PE as a result of the increased oxidative stress, as 
chronically elevated levels of NO, resulting from iNOS, can react with ROS to 
form peroxynitrite. Moreover, this increased production of ROS would be 
compounded by the decrease in antioxidant defense [314]. Indeed, PE is often 
associated with a decrease in antioxidant defences, such as catalase, GPx, SOD 
and glutathione S-transferase [118, 199]. In the general population, exercise 
training has been shown to enhance the expression of the antioxidants SOD and 
GPx[245-247]. It stands to reason that exercise training may also enhance their 
expression during PE and thus protect the mother from oxidative damage.  
Moreover, an immune reaction against paternal antigens on the fetus is considered 
a potential disease-initiating entity in some cases of PE. A preponderance of pro-
inflammatory reactions, as is the case during PE, has deleterious effects on the 
body, for instance causing endothelial dysfunction by targeting the coagulation 
pathway, vascular relaxation and oxidative stress[215, 216]. Minimizing 
circulating mediators like IFN- and IL-18, may reduce the prevalence and/or 
severity of PE. On the other hand, exercise training has been shown to produce 
anti-inflammatory effects, for instance by favouring the production of IL-6, IL-10 
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and IL-1RA and inhibiting that of TNF-α[248]. As such, exercise training may 
thus provide protection by minimizing the pro-inflammatory effects associated 
with PE and thus, measuring inflammatory mediators in the circulation of trained 
animals would be of interest[245].  
 
The effects of exercise training on PE prevention has currently been investigated 
in only two animal models, both of which have been published by our 
laboratory[287]. In both, the effects of exercise training before and during 
pregnancy were explored. Determining whether these benefits arise when exercise 
training is initiated during pregnancy needs to be addressed as there is data which 
suggests that it may have negative impacts. Indeed, Yeo et al. (2008) carried out a 
prospective study in which the effect on PE risk of two types of exercise was 
investigated when initiated at 18 weeks of pregnancy[277]. Although non-
significant, the walking women were more likely to develop PE then the women 
who followed a stretching program. Moreover, some studies have found PE risk to 
be increased with higher intensity exercise training that was initiated during 
pregnancy[273, 284]. Therefore, identifying the optimal intensity, type of exercise 
and frequency of training, if at all, are mandatory to determine what is beneficial 
for women at risk of the disease.  
 
Several studies have found that preeclamptic women are at an increased risk of 
developing CVD later in life[66, 67]. It would be of value to determine if this is 
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the case in our animal models. Subsequently, identifying which, if any, disease 
promoting entities, like for example the decrease in aortic MasR and ACE2 
observed among sedentary R
+
A
+ 
mice, persist post-partum may shed light into why 
PE patients are more susceptible to CVD. Protecting these at-risk women from 
prospective CVD is a major concern that must be examined.   
 
To date, the ACOG does not recommend that at-risk women take part in aerobic 
training during pregnancy[262]. Although several epidemiological studies have 
observed a protective effect of training on PE risk, these are considered 
insufficient as they are not randomized studies, the cohorts are too small and the 
mechanisms are ill-understood[285]. Conversely, our animal study has 
demonstrated that exercise training prevents the development of gestational 
features similar to those observed during SPE. Future studies are thus warranted to 
better determine the effect of exercise training in this target population. 
Additionally, animal studies are needed to corroborate our findings, and provide 
mechanistic insight into the benefits of exercise training. A clear understanding of 
their benefits on PE prevention will further entice research groups to carry out 
controlled large randomized studies on the effect of exercise training on PE risk. 
Without further investigation, the ACOG will not modify their guidelines 
concerning their exercise recommendations for at risk women.
  
 
Chapter 8 - Conclusion 
Our study investigating the effects of exercise training on SPE risk is the first 
animal study to demonstrate the protective effect of exercise training in a known 
at-risk population. This animal study allowed us to solely investigate the cause and 
effect relationship between exercise training and PE risk, as it was possible to hold 
many parameters constant, including environment and genetic background. Our 
results have helped elucidate potential mechanisms implicated in PE as well as 
those involved as a result of exercise training. This study represents a milestone 
for the future investigation of the effects of exercise training on PE risk in humans 
studies. 
 
To date, the ACOG does not recommend at-risk women to take part in aerobic 
training. This animal study warrants future studies be carried out to better 
determine the effect of training in at risk populations. The use of animals is by no 
means over. Investigating the mechanisms implicated, as well as the effect of 
exercise training during pregnancy alone are also needed to further support the 
recommendation of exercise training during PE. Several etiologies have been 
suggested to contribute to PE, and thus, each ought to be investigated to acquire a 
better understanding of the complexity of this disease with no known cure. 
Investigating the effects of exercise training in other animal models, as well as the 
mechanisms implicated, will also be important because of the multiple etiologies.  
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